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Abstract
Conventional pulse oximetry has limited accuracy in measuring blood oxygen sat-
uration in low saturation and perfusion scenarios. This limits the application of
pulse oximetry in patients suﬀering from peripheral vascular aictions.
A novel pulse oximetry system is presented in this study which proposes so-
lutions to these low saturation and perfusion issues. The presented system was
designed to overcome the low perfusion issues by inducing an artiﬁcial pulse in the
detected photoplethysmograph. A novel arterio-venous hypothesis was formulated
to extract arterial and venous saturation data from this artiﬁcial photoplethysmo-
graph using arterial-to-venous compliance ratios. Sensor wavelengths were selected
to provide high and low saturation accuracy, followed by an in vitro sensor cali-
bration procedure. System performance was validated by means of in vivo human
studies.
In vivo results indicate good accuracy for high saturation, with limited accuracy
in low saturation scenarios. The arterio-venous hypothesis was validated, indicating
that venous saturation information can be extracted from the artiﬁcial PPG.
Although inconclusive, results indicate that the proposed system might be able
to accurately monitor arterial and venous saturation in severe hypoperfusion scenar-
ios with recommended hardware and calibration modiﬁcations. It is recommended
that further studies into the presented system's performance are conducted.
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Uittreksel
Konvensionele `pulse oximetry' sisteme het beperkte akkuraatheid tydens die met-
ing van bloed suurstof saturasie in lae saturasie en perfusie gevalle. Dit beperk die
bruikbaarheid van `pulse oximetry' in pasiënte wat ly aan perifere vaskulêre siektes.
`n Nuwe `pulse oximetry' sisteem, wat oplossings vir hierdie lae saturasie en
perfusie beperkings voorstel, word in hierdie studie aangebied. Die voorgestelde
sisteem is ontwerp om die lae perfusie beperkings te oorkom deur `n kunsmatige
polsslag in die `photoplethysmograph' te induseer. `n Nuwe arterio-veneuse hipotese
is geformuleer om arteriële en veneuse saturasie inligting uit hierdie kunsmatige
polsslag te onttrek deur middel van `n arteriële-teenoor-veneuse styfheids verhoud-
ing. Die golﬂengtes wat gebruik is in die sensors, is spesiﬁek gekies om hoë en
lae saturasie akkuraatheid te verskaf. `n In vitro kalibrasie prosedure is gevolg om
die sensors vir hoë en lae saturasie te kalibreer, waarna die werkverrigting van die
sisteem getoets is deur middel van `n in vivo validasie prosedure.
Die in vivo resultate toon goeie akkuraatheid vir hoë saturasie, met beperkte
akkuraatheid vir lae saturasie. Die arterio-veneuse hipotese is gevalideer, wat aan-
dui dat veneuse saturasie wel uit die kunsmatige `photoplethysmograph' onttrek
kan word.
Alhoewel die resultate wat in hierdie studie aangebied word nie omvattend of
beslissend is nie, dui dit egter aan dat die voorgestelde sisteem dalk in staat kan
wees om arteriële en veneuse saturasie in uiters lae perfusie gevalle te meet. Ver-
beteringe sal egter aan die sisteem aangebring moet word in terme van hardeware
en kalibrasie, om `n meer gestandardiseerde metings metode te verseker. Verdere
navorsing oor die werkverrigting van die voorgestelde sisteem word ook voorgestel.
iii
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Introduction
Continuous, non-invasive and reliable blood oxygen saturation (SO2) information
might play a vital role in the choice of medical intervention in treating patients
suﬀering from peripheral vascular aictions. In treating patients suﬀering from
diseases such as meningococcemia and diabetes mellitus, medical intervention often
includes the surgical removal of tissue aﬀected by advanced hypoxia as a result of
ischaemia (Milonovich, 2007). The decision to amputate digits or limbs aﬀected by
necrosis and the severity of the amputation are currently based on an intermittent
and qualitative evaluation by the medical practitioner and not on a continuous and
quantitative oxygen supply and consumption background. Although continuous
saturation recording cannot serve as the sole parameter on which amputation is
based, it might provide the medical practitioner with a tool to enable a more
informed decision.
The current benchmark for the continuous and non-invasive monitoring of ar-
terial saturation (SaO2) is pulse oximetry. The application of conventional pulse
oximetry principles in monitoring peripheral vascular aictions is however, lim-
ited. Although accurate for SaO2 values in excess of 70-80%, studies have shown a
marked decrease in precision in pulse oximeter arterial saturation (SpaO2) values for
SaO2 values below 70-80% (Jensen et al., 1998; Carter et al., 1998; Razi and Hos-
sein, 2006; Bickler et al., 2005). Additionally, pulse oximetry principally depends
on the presence of a pulsatile arterial component. This pulsatile component is often
missing in ischaemic tissue. As conventional pulse oximeters are rendered unusable
by these ischaemic conditions and only measures SaO2, there is a need to develop
1
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an alternative system capable of continuously and non-invasively monitoring both
SaO2 and venous saturation (SvO2).
All pulse oximeters rely on the detection of an alternating (AC) absorption pat-
tern, however small, in a detected photoplethysmograph (PPG), caused by pulsatile
arterial blood. In the absence of this AC pattern, an error message is usually dis-
played. Although Chan and Smith (2003) addressed the absence of an AC pattern
by inducing an artiﬁcial AC pattern in the PPG, a system speciﬁcally designed for
SpaO2 and SpvO2 measurement accuracy in low saturation and severe hypoperfusion
scenarios is still needed.
This study presents the development of a modiﬁed pulse oximetry system to
non-invasively monitor SpaO2 and SpvO2 in low saturation and severe hypoperfu-
sion scenarios. The selection of the sensor hardware to facilitate low saturation
measurement is discussed, followed by a design overview of an artiﬁcial pulse gen-
erator for low perfusion applications. Thereafter, a system calibration by means of
an in vitro calibration procedure, to facilitate low saturation accuracy, is presented.
An in vivo human validation procedure and results are presented to validate sys-
tem performance in diﬀering physiological and saturation scenarios. Throughout
the calibration and validation procedures, results were tested against a photon dif-
fusion theory model provided by Schmitt (1991), which was modiﬁed to incorporate
the eﬀect of venous pulsations.
It is concluded that the designed system, as presented in this thesis, is not
suited for repeatable and accurate measurement of SpaO2 and SpvO2 in low satu-
ration and perfusion scenarios. The validation results do however seem to indicate
that continuous and non-invasive monitoring of SpaO2 and SpvO2 could possibly
be achieved with the designed system if speciﬁc adjustments are made to improve
measurement repeatability.
Chapter 2
Background
2.1 Blood Oxygen Saturation
The eﬃcient regulation of oxygen absorption and distribution by the cardiopul-
monary and cardiovascular systems is of cardinal importance to human wellbeing.
If tissue is deprived of a suﬃcient supply of oxygen for an extended period, cell
damage occurs which may eventually result in extended necrosis. On the other
hand, a surplus of oxygen can result in brain damage in neonatal patients. The
oxygen content of blood is thus an important indicator of cardiopulmonary and car-
diovascular function, resulting in some forms of blood oxygen content monitoring
being regarded as the ﬁfth vital sign.
Oxygen is transported by blood in two forms, namely, as solute in blood plasma
and bound to the pigment haemoglobin, found in red blood cells (RBCs). Approx-
imately 1.5% of the oxygen content of arterial blood is dissolved in blood plasma,
the remaining 98.5% is bound to haemoglobin (Martini and Bartholomew, 2003).
It can thus be safely assumed that the oxygen content of RBCs is a good repre-
sentation of the overall oxygen content of blood. Blood oxygen content is usually
described in terms of partial pressure or saturation, and although partial oxygen
pressure can be related to oxygen saturation, only the latter is important in the
context of this study.
SO2 is the concentration of oxygenated haemoglobin relative to the total con-
centration of haemoglobin in blood. As such, it is usually expressed as a percent-
age value. Adult blood usually contains four species of haemoglobin, namely oxy-
3
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genated haemoglobin (HbO2), reduced haemoglobin (Hb), methaemoglobin (MetHb)
and carboxyhaemoglobin (COHb) (Kamat, 2002). As MetHb and COHb do not
bind oxygen, SO2 can be deﬁned as functional and fractional, with functional SO2
neglecting the eﬀects of MetHb and COHb, while fractional SO2 takes the eﬀects
of MetHb and COHb into account. Unless otherwise stated, SO2 values stated in
this study will be functional.
SO2 values in the human circulatory system diﬀer according to the location
of blood in the system. Arterial blood has a high SO2, while venous blood has a
lower SO2. As such, arterial and venous saturation are expressed as SaO2 and SvO2,
respectively. Additionally, the measurement system used is normally also indicated,
with SaO2 indicating arterial SO2 measured by means of a co-oximetry blood gas
analysis and SpO2 indicating arterial SO2 measured by means of pulse oximetry.
Historically, the focus of SO2 measurements has been on arterial oxygen content,
not necessitating further expansion of the SO2 term. In this study however, arterial
and venous SO2 values, measured by means of co-oximetry and pulse oximetry,
were discussed. Arterial SO2 measured by means of co-oximetry was thus stated
as ScaO2, while venous SO2 measured by means of pulse oximetry was stated as
SpvO2.
2.2 SO2 Monitoring Systems
Existing systems for measurement of the O2 content of blood were studied to iden-
tify the system best suited to the system speciﬁcations of this study. SO2 moni-
toring systems can be divided in two categories, namely, invasive and non-invasive.
Only non-invasive measurement of SO2 was important in the context of this study.
2.2.1 Transcutaneous Clark Electrode
The Clark electrode is a polarographic method of measuring the partial pressure of
O2 (pO2) in a blood sample. Although not a direct SO2 measurement method, pO2
can be related to SO2. Two electrodes, connected by an external bias source, are
immersed in an electrolytic potassium chloride solution. The potassium chloride
solution is separated from the blood sample by means of an O2-permeable Teﬂon
or polypropylene membrane that allows O2 to diﬀuse into the electrolytic solution.
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pO2 is measured by means of an oxidation/reduction reaction occurring at the
electrodes. O2 is reduced at a noble metal cathode to form hydroxyl ions. This
reaction consumes 4 electrons. The hydroxyl ions diﬀuse to a silver anode where
silver is oxidised to silver ions. This reaction liberates a single electron. The silver
ions combine with chloride ions to form silver chloride. Electrons liberated in the
oxidation reaction at the anode migrates to the cathode to enable the reduction
reaction. The ﬂow of electrons, and thus the current, is directly proportional to
the rate of O2 reduction at the cathode and thus the concentration of O2 in the
electrolytic solution. The concentration of O2 in the solution is representative of
the rate of O2 diﬀusion across the membrane and thus pO2. pO2 is thus directly
proportional to current ﬂowing through the external bias source.
The transcutaneous Clark electrode is a slightly modiﬁed version of the polaro-
graphic Clark electrode. Small heating coils are included in the housing of the
sensor to cause vasodilation of the skin, enabling non-invasive pO2 measurement
through the skin (Enderle et al., 2005).
2.2.2 Blood Oxygen Level Dependent Magnetic Resonance
Imaging (BOLD MRI)
MRI is a three-dimensional imaging method that is frequently applied in medical
scenarios. Medical MRI frequently uses the interaction of hydrogen atoms with an
applied magnetic ﬁeld to form an image of the human body. A hydrogen atom
contains a proton in its nucleus, resulting in a small magnetic ﬁeld as the nucleus
spins. The frequency of this magnetic moment is termed the Larmor frequency
and is unique to hydrogen. If the atom is placed in a strong magnetic ﬁeld, the
hydrogen atom aligns with the magnetic ﬁeld so that the axis of nucleus spin is
aligned with the magnetic ﬁeld. Should a radio frequency magnetic ﬁeld be applied
perpendicular to the static magnetic ﬁeld at the Larmor frequency, the hydrogen
atoms are exited to a state where the axis of nucleus spin is not aligned with the
static ﬁeld. When the perpendicular magnetic ﬁeld is shut oﬀ, the hydrogen atoms
return to the equilibrium state, emitting a radio frequency signal that is detected
by the coils of the static ﬁeld magnet. These radio frequency signals are used to
form a spatial image of tissue, based on the relative concentrations of hydrogen
atoms in the tissue.
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Functional MRI is a form of MRI that is used to measure brain activity. The
increase in neural activity is monitored by means of a mechanism referred to as
the blood-oxygen-level dependent (BOLD) eﬀect. Changes in neural activity calls
for changes in the O2 supply. By monitoring the O2 content of regional blood
vessels, an indication of neural activity can be obtained. The monitoring of O2 is
achieved by means of measuring the magnetic susceptibility of haemoglobin, with
oxygenated blood being dimagnetic and deoxygenated blood being paramagnetic
(Enderle et al., 2005). Signal processing is conducted by subtracting MRI images
of the brain before and after task initiation. This is done because the changes
in magnetic parameters in BOLD MRI are very small and result in BOLD MRI
readings being reported as percentage change in the BOLD MRI signal (Enderle
et al., 2005).
2.2.3 Digital Infrared Thermal Imaging (DITI)
DITI is not an O2 content sensor, but rather a measure of tissue perfusion. Tissue
perfusion is closely related to the supply of O2.
DITI is a non-invasive method of measuring skin surface temperature. An in-
frared camera is used to measure skin temperature by relating the infrared radiation
of skin to skin temperature by means of Planck's Law (Jones and Plassmann, 2002).
A spectral image is formed, relating diﬀerent skin temperatures to diﬀerent colours.
Skin surface temperature is indicative of the extent of dermal perfusion (Jones
and Plassmann, 2002). Dermal vasodilation will result in increased blood ﬂow in
the dermis, resulting in an increase in skin surface temperature. As modern DITI
systems have a sensitivity of up to 0.1 degrees Celsius, minor changes in tissue
perfusion can be detected. As such, DITI can provide valuable information on a
range of physiological processes that aﬀect blood perfusion.
2.2.4 Pulse Oximetry
Pulse oximetry is a non-invasive method of directly measuring SO2. This method
is used extensively in modern ICU's and general monitoring.
SO2 measurement is based upon the diﬀerent optical absorption properties of
HbO2 and Hb. Light, at two diﬀerent wavelengths speciﬁcally chosen to optimise
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system performance, is shone onto the tissue of interest. A photodetector detects
the intensity of light that is transmitted through, or reﬂected from, the tissue.
These intensities are then related to SO2. The detected light from the vascular
bed has alternating intensity levels as a result of pulsatile arterial blood, enabling
the pulse oximetry system to discern between the absorption by blood or bloodless
tissue, skin and bone. By considering only the optical absorption of blood, the SO2
of blood is then calculated. This measurement method will be discussed in more
detail in Chapter 3.
2.2.5 Near-Infrared Spectroscopy
Near-infrared spectroscopy (NIRS) is a optical method of non-invasively measuring
tissue oxygen saturation.
The use of NIRS to measure the concentration of diﬀerent tissue chromophores
is based upon a modiﬁed version of Beer-Lambert's law (Elwell and Hebden, 1999),
which states that the absorption of light in an optically absorbing compound is re-
lated to optical pathlength, chromophore absorption coeﬃcients and the concentra-
tions of all chromophores in the compound. Beer-Lambert's law will be discussed
in more detail in Section 3.1. Modern spectrometers, utilizing NIRS principles,
usually utilize four laser diodes and a photodetector to measure reﬂected light in-
tensities from the tissue of interest. These intensities are then related to tissue
chromophore concentrations by means of the modiﬁed Beer-Lambert's law that ac-
counts for variations in optical pathlength and scattering losses (Elwell and Hebden,
1999).
2.2.6 Laser Doppler Flowmetry
Laser Doppler Flowmetry (LDF) is an established method of non-invasively moni-
toring relative changes in tissue perfusion. As such it is not a O2 content sensor, but
is used for monitoring blood ﬂow in scenarios including heart monitoring, trans-
luminar coronary angioplasty and tissue blood ﬂow on the body surface (Enderle
et al., 2005).
LDF is based upon the Doppler phenomenon when a moving object causes a
frequency shift in incident light. This frequency shift, called Doppler shift, can
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be related to the velocity of the moving object. Low power laser light is reﬂected
from the tissue of interest and collected by means of a light sensitive probe. The
Doppler shift is then calculated and related to blood ﬂow velocities in the tissue.
These velocities are used as an indicator of tissue perfusion.
2.3 O2 Monitoring in Low Saturation and
Perfusion Scenarios
In patients suﬀering from peripheral vascular aictions, low peripheral saturation
and perfusion conditions are often present. Low perfusion conditions are also of-
ten present in surgical skin grafts. Medical practitioners treating these conditions
might beneﬁt from the continuous and non-invasive monitoring of the O2 supply
and demand scenarios at the aﬀected tissue. The monitoring of ischaemic digits
in patients suﬀering from low peripheral saturation and perfusion as a result of
meningococcemia forms the basic motivation of this study, although the monitoring
of conditions such as diabetes mellitus, surgical skin grafts or peripheral vascular
disease might deliver analogous results.
Meningococcemia is a severe febrile systematic disease, characterized by an
acute infection of the bloodstream and the resulting inﬂammation of the blood
vessels, known as vasculitis (Ramos-e-Silva and Pereira, 2005; Wener, 2005). In-
dividuals suﬀering from severe cases of meningococcemia often display large and
widespread haemorrhagic purpuric lesions (Ramos-e-Silva and Pereira, 2005). Large
purpuric and necrotic areas are characteristic of disseminated intravascular coagu-
lation (DIC) present in severe cases of meningococcemia. Purpuric lesions on the
knees and feet of a baby aﬀected by meningococcemia can be seen in Figure 2.1.
Antibiotic administration is the standard treatment that is used, with penicillin
G, chloranphenicol and some cephalosporins being the drugs of choice (Ramos-
e-Silva and Pereira, 2005; Mahmud and Shadab, 2007; Milonovich, 2007). The
restoration of circulatory function is also aggressively handled, while surgical re-
moval of digits aﬀected by advanced ischaemia or hypoperfusion might be necessary
(Milonovich, 2007). The decision whether to amputate depends on a balance be-
tween a possible further progression of hypoxia into lesser aﬀected tissues and saving
a digit that can possibly recover some functionality.
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Figure 2.1: Purpuric lesions on knees of baby
Recently, Dippenaar et al. (2006) studied the treatment of tissue ischaemia by
means of medicinal leeches, Hirudo Medicinalis. While feeding, these leeches inject
the tissue with saliva, containing active products that reduce and reverse many
of the processes contributing toward tissue ischaemia. Dippenaar et al. (2006)
applied H. Medicinalis leeches for four consecutive days to the left hand of a 5-
week old female infant. A deﬁnite improvement in tissue perfusion was noted,
with the largest improvement being noted after the ﬁrst day's treatment. It was
postulated that the improvement was due to the vasodilatory eﬀects, improved
capillary permeability, platelet inhibition and an attenuation in endothelial damage.
Leech treatment on an ischaemic hand can be seen in Figure 2.2.
Evaluation of the degree of treatment success is currently based on a visual
inspection of tissue perfusion, with conventional invasive and non-invasive O2 mon-
itoring methods rendered ineﬀective. An invasive blood gas analysis is rendered
ineﬀective as a result of the advanced degree of coagulation present in the digits,
the diﬃculty in obtaining a blood sample from the ﬁnger of a neonate and its inter-
mittance. The measurement of pO2 by means of a transcutaneous Clark electrode
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Figure 2.2: H. Medicinalis treatment of ischaemia
is hindered by the dependence of measured values on the degree of tissue perfusion
(Tremper, 1984). Although measured pO2 values might be indicative of changes
in tissue perfusion, a reliable and quantitative measure of the O2 content of the
blood would not be possible in extreme cases of ischaemia. BOLD MRI, on the
other hand, is capable of providing qualitative measurements of blood oxygenation,
but is limited by its intermittance and cost. As mentioned earlier, DITI is only
capable of measuring tissue perfusion and not the O2 content of blood. Although
DITI has been used in studies on occlusive vascular disorders (Jones, 1998), the
quantitative monitoring of tissue O2 content is not possible. Conventional pulse
oximetry is ineﬀective as a result of the absence of pulsatile blood behaviour in
the occluded tissue. The measurement of tissue oxygen saturation by means of
NIRS would be a good indicator of the status of the aﬀected tissue, but due to a
lack in available equipment and the cost of acquiring a suitable system, it was not
a viable option. As with DITI, LDF values are only a relative measure of blood
CHAPTER 2. BACKGROUND 11
perfusion and as such cannot provide a quantitative measurement of the O2 status
of ischaemic tissue.
Additionally, the O2 content of venous blood might be an important indicator
of the status of aﬀected tissue. Normally, pO2 in the arterial and venous circula-
tion diﬀers by approximately 60 mmHg (Martini and Bartholomew, 2003). This is
indicative of healthy tissue, where O2 is consumed and CO2 is formed. In tissue
aﬀected by extended necrosis, the amount of O2 consumed would be much less, re-
sulting in a decrease in pO2 diﬀerence between arterial and venous circulation. An
elevated local venous pO2 might thus be indicative of extended necrosis, although
the validity of this statement would have to be tested in a further study. None
of the O2 monitoring methods mentioned above is suited to the continuous and
non-invasive monitoring of SvO2 (or venous pO2).
As mentioned earlier, the eﬀective monitoring of the degree of medicinal leech
treatment success on meningococcemia induced digital ischaemia forms the basic
motivation for this study. This was attempted by measuring arterial and venous
oxygen saturation at the aﬀected site through the use of an adapted pulse oximetry
system capable of operating in a non-pulsatile environment. By continuously and
quantatively monitoring both arterial and venous SO2 in the aﬀected tissue, the
medical practitioner might be able to make a more informed decision regarding
other therapeutic modalities such as medicinal leeches or ultimately amputation.
Chapter 3
Pulse Oximetry
The measurement of SO2, based on the light absorption properties of oxygenated
and deoxygenated blood, is called oximetry. More particularly, oximetry is based
upon the relative concentrations of oxygenated HbO2 and reduced hemoglobin Hb
in blood, as these are the major factors that determine SO2. HbO2 and Hb have
diﬀerent light absorption properties and the eﬀects of their relative concentrations
can be seen in the distinctly diﬀerent colors of oxygenated and deoxygenated blood.
Pulse oximetry is a non-invasive form of oximetry, where HbO2 and Hb concen-
trations, and thus SO2, are determined based upon the distinctive light absorption
behaviour of tissue due to the pulsatile behaviour of blood in the arterial branch
of the vascular bed.
3.1 Operating Principle
Oximetry is based upon Beer-Lambert's Law, which states that the amount of
light absorbed by an absorbing species dissolved in a non-absorbing compound is
a function of the speciﬁc extinction coeﬃcient (se) of the species, the mean photon
path length through the species (l) and the concentration of the species (x). This
law can be summarized as follows (Enderle et al., 2005):
It = Io × 10−se.l.x (3.1)
or alternatively (Elwell and Hebden, 1999),
12
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A = log10
[
Io
It
]
= se.l.x (3.2)
with It the transmitted light intensity, Io the incident light intensity and A
the attenuation. This relationship only holds for a singular species dissolved in a
non-absorbing compound. If more than one absorbing species is present in the non-
absorbing compound, Equation 3.2 can be stated as follows (Elwell and Hebden,
1999):
A = log10
[
Io
It
]
= [se1.x1 + se2.x2 + se3.x3 + ...+ sen.xn] .l (3.3)
where the combined factor se.x is also called the absorption coeﬃcient of the
absorbing species. As can be seen from Equation 3.3, a non-absorbing medium
containing three diﬀerent absorbing species would require three diﬀerent equations
to solve for x if A, se and l was known.
Tissue contains a large number of diﬀerent absorbing species. These consist
of compounds contained in the skin, the dermis, bone and blood. To solve the
oximetry form of Equation 3.3 for the concentrations of HbO2 and Hb in tissue
would require a large number of independent equations. This would not be a
viable option. Fortunately, the light absorption behaviour of tissue has some very
distinctive characteristics that enables the calculation of x for HbO2 and Hb using
only two independent equations.
Light absorption in tissue can be shown in the form of a photoplethysmograph
(PPG), as seen in Figure 3.1a. This PPG is recorded using a pulse oximeter, shown
in Figure 3.1b, consisting of two high output LEDs and a highly sensitive silicon
photodetector. The LEDs are of diﬀerent wavelengths, one typically in the red (660-
700 nm) wavelength range and the other in the infrared (880-950 nm) wavelength
range. Wavelengths are selected, based on the absorption coeﬃcients of HbO2 and
Hb (Figure 3.2 (Prahl, 1998)), to maximize sensor sensitivity and repeatability
(Mannheimer et al., 1997). The pulse oximeter setup shown in Figure 3.1 is that
of transmission pulse oximetry, whereas reﬂection pulse oximetry has the LEDs
and photodetector on the same side of the ﬁnger or tissue. Light emmitted by the
LEDs propagates through the ﬁnger and its absorbing species and is detected by
the photodetector. The light intensity detected by the photodetector is represented
by the PPG. The PPG shown in Figure 3.1 is that of only one LED, whereas typical
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PPGs will have two diﬀerent data sets, one for each LED. The individual LEDs
are sequentially switched and the data acquired by the photodetector separated for
each LED.
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Figure 3.1: Photoplethysmograph Model and Transmission Pulse Oximeter
As can be seen from the PPG in Figure 3.1a, the light absorption of tissue
has two distinct components, namely an arterial pulsatile (AC) component and a
baseline component (DC). The AC component of the PPG is due to the modulation
in photon path length as the arterial branch of the vascular bed expands and
contracts during systole and diastole. The DC component of light absorption is
due to the static absorption of skin and bloodless tissue, as well as the absorption
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Figure 3.2: Absorption Spectrum for Oxygenated and Deoxygenated Haemoglobin
(Prahl, 1998)
of resident arterial and venous blood. The AC component is thus only dependent on
pulsatile blood behaviour, while the DC component includes the absorption by the
rest of the light absorbing species. The absorption by blood can thus be separated
from the absorption by the rest of the absorbing species by simply separating the
AC and DC components of the PPG.
The amplitude of the AC component of the PPG is dependent on SaO2, as
the relative concentrations of HbO2 and Hb in the arterial blood determine the
absorption of light, as stated by Equation 3.3. HbO2 and Hb are not the only
strong absorbers in blood, however, with methaemoglobin (MetHb) and carboxy-
haemoglobin (COHb) also having strong absorption coeﬃcients in the selected
wavelength ranges. The eﬀect of these additional haemoglobin species are usu-
ally neglected due to their small concentrations in blood under normal conditions
(Kamat, 2002). This gives rise to the term `functional haemoglobin saturation',
as opposed to `fractional haemoglobin saturation' where the eﬀects of MetHb and
COHb are included. The DC component is also dependent on SaO2 to a lesser
extent, as the residual arterial blood also absorbs light according to HbO2 and Hb
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concentrations. Additionally, the incident light intensity also aﬀects the AC compo-
nent amplitude. Normalizing the original AC component with the DC component
compensates for the residual blood and incident light intensity variations (Sinex,
1999). The normalized AC component of the PPG is now relatively independent
of any DC component variations (Enderle et al., 2005).
As can be seen from Equation 3.3, the calculation of the concentrations of
HbO2 and Hb requires two diﬀerent equations, resulting in a need for two diﬀerent
PPGs. This is the reasoning behind using two LEDs in a pulse oximeter probe. In
fractional haemoglobin saturation calculations, more PPGs are needed to satisfy
Equation 3.2 for more variables, resulting in up to ﬁve LEDs being using in more
comprehensive systems (Aoyagi, 2003). The normalized AC components of the red
PPG is divided by the normalized AC component of the infrared PPG to obtain a
normalized ratio R that is highly dependent on the concentrations of HbO2 and Hb,
and thus SaO2, and relatively independent of light absorption by the DC species.
The calculation of R can be seen below as Equation 3.4.
R =
ACr/DCr
ACir/DCir
(3.4)
In early pulse oximeters, R was used in conjunction with Beer-Lambert's Law
to calculate SpaO2. Beer-Lambert's Law does not however, take the eﬀects of light
scattering, reﬂection and diﬀusion into account, all being major factors in light
propagation through tissue (Stabile and Reynolds, 2002), leading to gross overesti-
mation of SpaO2 (Sinex, 1999). Scattering, reﬂection and diﬀusion factors result in
Beer-Lambert's Law being inaccurate in most scenarios, especially low saturation
conditions (Coetzee and Elghazzawi, 2000). Several alternative and more compli-
cated models have been developed that take scattering, reﬂection and diﬀusion into
account (Schmitt, 1991; de Kock and Tarassenko, 1991, 1993; Lindberg et al., 1995),
but the validity of these models under a wide range of physiological scenarios are
questionable (Coetzee and Elghazzawi, 2000).
Most pulse oximeter manufacturers thus resort to an empirical calibration ap-
proach to relate R to SaO2. Two calibration approaches exist, namely in vivo and
in vitro calibration procedures. These procedures will be discussed in more detail in
Section 4.5.1, but manufacturers currently employ in vivo desaturation procedures
to obtain the calibration curves (Webster, 1997). These calibration procedures
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result in calibration curves where R is related to SaO2 under conditions closely
resembling normal physiological conditions. R values calculated from the red and
infrared PPGs are compared to the calibration curves, resulting in the calculated
SpaO2 value.
3.2 Pulse Oximetry in Low Saturation Value
Scenarios
The proliferation of pulse oximeters in modern ICUs has led to a large variety of
studies into pulse oximeter performance, in both high and low saturation scenarios
(Lee et al., 2002; Bickler et al., 2005; Razi and Hossein, 2006; Lindholm et al., 2007;
Van de Louw et al., 2001; Severinghaus et al., 1989; Severinghaus and Naifeh, 1987;
Uystepruyst et al., 2000; Carter et al., 1998). The above mentioned studies show
increases or decreases in SpaO2 bias (mean diﬀerence between measurement method
and golden standard) and a decrease in SpaO2 precision (standard deviation (SD) of
error) as SaO2 decreases below 70-80%, while SpaO2 values above 70-80% generally
agree closely with SaO2.
In a recent meta-analysis of pulse oximetry performance, Jensen et al. (1998)
concluded that historically, pulse oximeters were accurate to within ±2% in the
SaO2 range 70-100%, but that accuracy deteriorates rapidly for SaO2 ≤70%. These
data were collected by studying pulse oximeter performance studies from 1974 to
1994.
Carter et al. (1998) compared the performance of Ohmeda 3700 and Hewlett-
Packard M1020A pulse oximeters in paediatric patients with SaO2 readings below
90%. Bias and precision values for the Ohmeda system was -2.8±4.8% (SaO2 ≥75%)
and -0.8±8% (SaO2 ≤75%). A marked increase in SpaO2 variability for SaO2 ≤75%
was thus observed, although bias was improved.
In a study done by Razi and Hossein (2006), the performance of a pulse oxime-
ter on 152 subjects diagnosed with chronic obstructive pulmonary disease was an-
alyzed. SpaO2 and ScaO2 values measured for SaO2 ≥90% was 94.17±3.71% and
94.37±2.18% (mean±SD), while SpaO2 and ScaO2 values measured for SaO2 ≤80%
was 74.4±10.24% and 70.63±9.13%. Discrepancies between SpaO2 and ScaO2 thus
became more pronounced for SaO2 ≤80%.
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Bickler et al. (2005) studied the eﬀect of skin pigmentation on SpaO2 in a group
of 11 subjects with darkly pigmented skin and 10 subjects with lightly pigmented
skin. SpaO2 values for the darkly pigmented subjects showed substantial overes-
timation of SaO2 in the range 60-70%. SpaO2 values for the lightly pigmented
subjects showed bias values in the range -1.62 to 1.91% for the three tested pulse
oximeters, while precision values were within the range ± 1.6 to ± 3.42%.
It can thus be concluded from the above-mentioned studies, that SpaO2 bias
and precision deteriorates for SaO2 ≤80%. The studies do not agree on over or
underestimation of SaO2, but do indicate a pronounced decrease in precision. These
errors may be due to a number of reasons.
Firstly, there is the issue of pulse oximeter calibration. As mentioned in Sec-
tion 3.1, most pulse oximeter manufacturers use an in vivo calibration procedure.
During this procedure, R values are collected on human volunteers that are system-
atically desaturated by breathing air with an increasingly leaner mixture of oxygen
(Sinex, 1999). ScaO2 values are measured at each data collection stage using a
reference in vitro co-oximetry system. A general calibration curve is obtained by
ﬁtting the R and ScaO2 data of a large number of volunteers. This calibration pro-
cedure can only be conducted for SaO2 ≥75-80% due to ethical ramiﬁcations such
as possible hypoxic brain damage for SaO2 ≤75-80% (Stabile and Reynolds, 2002;
Sinex, 1999). Extrapolation of the data for SaO2 ≥75-80% is used for SaO2 below
this level (Kelleher, 1988; Wukitsch et al., 1988). The inherent calibration errors as
a result of the data extrapolation might be a reason for deteriorating performance
at low SaO2 values.
Secondly, slight variations in LED output wavelengths generate large variations
in calculated SpaO2 values in low saturation scenarios (Carter et al., 1998). The
eﬀects of LED output wavelength discrepancies, as described by Wahr and Tremper
(1995), although negligible at high SaO2, become more pronounced at low SaO2.
Thirdly, the high absorption coeﬃcient ofHb causes strong absorption of the red
wavelength at low saturations. This causes a disproportionally small AC component
in the red PPG. To eﬀectively use the red PPG, the sensor hardware compensates
for the increased red wavelength absorption by increasing LED driving current and
photodetector gain to increase the AC amplitude of the red PPG. Unfortunately,
this also ampliﬁes electronic and physiological noise, resulting in misleading SpaO2
values (Stabile and Reynolds, 2002; Reynolds et al., 1992).
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Fourthly, ampliﬁed multiple scattering eﬀects, as described by Mannheimer
et al. (1997) and Shimada et al. (1984), may also aﬀect low SpvO2 calculations.
In these studies, it was postulated that these scattering eﬀects are due to discrep-
ancies between changes in the mean photon path lengths (l) in Equation 3.1) of the
two wavelengths used. The changes in mean photon path length resulted from tissue
perturbations for calibration and in vivo use. Tissue perturbations were described
as physiological tissue changes that signiﬁcantly aﬀect light propagation properties.
It was postulated that mean photon path length mismatches are negligible at high
saturation values, but that it becomes more important in low saturation scenarios.
Most studies on measures to improve pulse oximeter accuracy in low satura-
tion scenarios have focused either on improving the accuracy of the calibration
curves (Zonios et al., 2004; Mannheimer and Porges, 2004) or minimizing the ef-
fects of tissue perturbations on pulse oximeter performance (Casciani et al., 1995;
Mannheimer et al., 1997).
Zonios et al. (2004) presented a semi-empirical calibration approach to improve
the accuracy of calibration curves at low saturations. The authors presented an
exact solution to the transmission of light through human tissue by grouping all
calibration uncertainties together into a single uncertainty parameter. This un-
certainty parameter was included due to the fact that the number of unknowns
in the exact solution of the pulse oximetry problem exceeds the number of known
parameters. By grouping all the calibration unknowns into a single parameter, the
application of the exact solution to pulse oximetry was made possible. The uncer-
tainty parameter was empirically determined during in vivo desaturation studies
on sheep fetuses where at best linear ﬁt R and ScaO2 data was conducted. This
semi-empirical calibration study displayed marked improvements in SpaO2 bias and
precision.
In patent documentation presented by Mannheimer and Porges (2004), the au-
thors described a pulse oximetry system with a piece-wise calibration curve. Mod-
ern pulse oximeters utilize physiological parameters to select an appropriate cali-
bration curve from diﬀerent sets of in vivo calibration curves stored in the system
(Nellcor Technical Staﬀ, 2004). Mannheimer and Porges (2004) developed this
concept further by developing piece-wise calibration curves that take the range of
SpaO2 into account. The segments of the calibration curves were obtained by ap-
proximating only in vivo calibration data for the speciﬁc SaO2 range. Diﬀerent
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calibration curves were selected based on physiological parameters, while speciﬁc
calibration curve segments were selected based on the SpaO2 range.
Casciani et al. (1995) and Mannheimer et al. (1997) described pulse oxime-
try systems where the selection and placement of LEDs are speciﬁcally based on
improved performance at low saturations. It was postulated that the deteriorat-
ing bias and precision of pulse oximeters are as a result of mean photon path
length mismatches between the wavelengths used due to tissue perturbations, as de-
scribed above. Tissue perturbations were described as physiological tissue changes
that signiﬁcantly aﬀect light propagation properties. Perturbations listed included
variations in tissue composition, haemoglobin concentration and application force
between the sensor and measured tissue Casciani et al. (1995). The hypothesis
proposed by Mannheimer et al. (1997) stated that the mean photon path length
diﬀerences for a 660/910 nm LED combination are well-matched between calibra-
tion and actual use at high saturation. This match deteriorates however, at low
saturations. A re-selection of LED wavelengths was recommended based on an
improved match between mean photon path length diﬀerences for calibration and
actual use at low saturation. It was demonstrated by Mannheimer et al. (1997),
using Monte Carlo and photon diﬀusion models, that a 735/890 nm LED combina-
tion is optimally suited for low saturation scenarios, even though sensor sensitivity
to SaO2 changes deteriorated.
3.3 Pulse Oximetry in Low Perfusion Scenarios
The use of pulse oximetry to determine SpaO2 accurately and repeatably is depen-
dent on the presence of a clearly detectable AC component in the PPG. This AC
component is used to calculate R, as described in Section 3.1. Unfortunately, the
AC component is often missing in critically ill patients where accurate SpaO2 val-
ues are most important. Patients suﬀering from sepsis, hypothermia, hypovolemia,
peripheral vascular disease, diabetes and various forms of shock often exhibit se-
vere peripheral hypoperfusion (Schallom et al., 2007; Sinex, 1999). Additionally,
patients that have Raynaud's phenomenon may also exhibit poor pefusion (Kamat,
2002). Low peripheral perfusion will inevitably result in a small AC component,
complicating the procedure of separating PPG AC and DC components in an en-
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vironment where signal-to-noise ratios are low. Hypoperfusion states have been
known to lead to pulse oximeter error messages of `Low Signal Quality' or `In-
adequate Signal' (Kamat, 2002; Pologe, 1987). The importance of accurate SpaO2
values in critically ill patients has thus led to numerous studies into the performance
of pulse oximeters in low perfusion scenarios (Schallom et al., 2007; Jubran, 2004;
Cooke, 2002, 2000; Villanueva et al., 1999; Lutter et al., 2001; Shah and Estanol,
2006; Hummler et al., 2006, 2004).
Schallom et al. (2007) conducted a study on pulse oximeter performance in
decreased peripheral perfusion scenarios. A study population of 30 critically ill
patients at risk of decreased peripheral perfusion was used. Two diﬀerent pulse
oximeters were tested, namely the Nellcor Oximax N-595 and the Philips CMS.
SpaO2 performance was stated as -2.61±3.61% (bias±precision) for the N-595, while
the performance of the CMS model was given as -3.84±6.91%. The N-595 displayed
measurement failures for 7% of the study population, while the CMS failed to
display a measurement for 10% of the study population. The older CMS model
thus displayed inferior performance in low perfusion scenarios to that of the newer
N-595 system, providing evidence that advances in pulse oximetry technology has
led to better performance.
Studies done by Cooke (2000) and Cooke (2002) examined low perfusion perfor-
mance diﬀerences in a total of 19 diﬀerent pulse oximeters using a Bio-Tek Index
2MF SpO2 simulator. Simulated low perfusion scenarios were monitored using
the diﬀerent pulse oximeters and the signal sensitivity values recorded where each
oximeter ceased to function correctly. Signal sensitivity was deﬁned as ACir/DCir.
Sensitivity values for individual pulse oximeters spanned a wide range, with the
best values being recorded for the Nellcor N-395, Masimo MS-3, OSI Medical 2100
and Dolphin Medical DD 3000 pulse oximeters as 0.05%, 0.06%, 0.06% and 0.06%,
respectively. The worst sensitivity recorded was that of the NovaMetrix 513 model
with a value of 0.4%.
Shah and Estanol (2006) and Lutter et al. (2001) conducted similar studies on
the sensitivity and speciﬁcity of various modern pulse oximeter models in detect-
ing hypoxic events. Shah and Estanol (2006) conducted rapid desaturation and
resaturation studies with motion artifacts on 10 healthy volunteers, while Lutter
et al. (2001) studied 108 subjects undergoing general or emergency surgery without
motion artifacts. Sensitivity was deﬁned as the system's ability to detect a hypoxic
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event, while the ability to generate true alarms based on hypoxic events was termed
as speciﬁcity. Best sensitivity and speciﬁcity values of 95% and 97% were recorded
for the Masimo Radical model during the Shah and Estanol (2006) study, while
the Lutter et al. (2001) study recorded very similar values for all three tested pulse
oximeters.
Presently, low perfusion pulse oximetry technology is based on the adaptive
ﬁltering of the PPG to accurately extract R from the small AC component, as
well as the minimization of noise contamination of the PPG. This is in contrast
with the historical methods of simply increasing LED output intensity until an
AC component could be extracted from the PPG (Tremper and Barker, 1989). As
explained by Sinex (1999), this increases unwanted artifact ampliﬁcation, resulting
in noise contamination of the calculated R.
The Masimo Corporation was the ﬁrst company to receive FDA clearance to
claim accurate measurement of SpaO2 in decreased peripheral perfusion scenarios
(Masimo Corporation, 2006). The accurate low perfusion measurement of SpaO2
was achieved through the design of the sensor hardware to minimize electronic noise
contamination of the PPG, as well as an innovative signal processing algorithm that
uses adaptive ﬁlters to eliminate the eﬀects of noise artifacts (Masimo Corporation,
2006).
The application of adaptive ﬁltering in biomedical signals such as a PPG has
a lot of merit. Unfortunately, the adaptive ﬁlter needs a reference signal (RS) to
calculate the ﬁlter coeﬃcients in real-time. This reference signal is generally not
available. Masimo solved this problem with their Signal Extraction Technology
(SET) concept. SET extracts a reference signal from the red and infrared PPGs
by manipulating the equation used to calculated R in conventional pulse oximetry.
The reference signal is calculated by using the relationship stated as Equation 3.5
(Masimo Corporation, 2005).
RS = Ir − [R× Iir] (3.5)
As can be seen from Equation 3.5, RS is dependent on R. Masimo now uses a
technique it calls Discrete Saturation Transform (DST) to calculate SpaO2 using
the reference signal and infrared PPG. A reference signal generator creates a range
of reference signals that corresponds with R values correlated with SpaO2 values
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ranging from 0-100%. These reference signals are used as input to an adaptive
ﬁlter or adaptive noise canceller (ANC) to aggresively ﬁlter the infrared PPG. The
ﬁltered PPG is then analyzed for output power. The SET system can be seen as
Figure 3.3.
Figure 3.3: Masimo SET (Masimo Corporation, 2005)
As can be seen in Figure 3.3, the analysis of PPG output power can be presented
in an output power graph. This graph can be interpreted by looking at the reference
signal range. If the R value selected to calculate a reference signal is incorrect, the
reference signal would be an inaccurate representation of PPG noise, resulting in
signiﬁcant parts of the true PPG signal being ﬁltered out as well. This would result
in a low output power ﬁltered PPG. If the R value, however, is correct, the reference
signal would be representative of PPG noise, resulting in only PPG noise being
ﬁltered out. The ﬁltered PPG would thus have signiﬁcant output power. These
peaks in output power resulting from R values corresponding to SpaO2 and SpvO2
are identiﬁed and converted to SpaO2 and SpvO2 using a conventional calibration
curve.
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Masimo SET pulse oximetry has been shown to be superior in both sensitivity
and speciﬁcity to conventional pulse oximeters in a number of low peripheral perfu-
sion studies (Lutter et al., 2001; Graybeal and Petterson, 2004; Shah and Estanol,
2006; Cooke, 2000). The calculation of SpaO2 is, however, still dependent on the
detection of an AC component, however small, in the PPG.
In a study done by Foo and Wilson (2006), accelerometer outputs were used as
input to an adaptive ﬁlter. The accelerometer outputs quantiﬁed motion artifact
contamination of the PPGs, resulting in a reference signal that was used by the
adaptive ﬁlter to cancel the corresponding motion artefact noise. Zero-phase digital
ﬁltering was also used in poor peripheral perfusion scenarios. The system was
however, still dependent on the detection of an AC component in the PPG.
Coetzee and Elghazzawi (2000) proposed an adaptive ﬁltering system that uses a
synthetic reference signal derived from heart rate and an idealised pulse waveform
shape. A clean segment of the PPG was selected from which the heart rate is
calculated. A basic pulse signal waveform was derived from adult volunteer data
and an individualized idealized pulse shape calculated for the PPG data. The pulse
shape and heart rate data were used to create a synthetic reference signal that was
used to adaptively ﬁlter the original PPG data to obtain a relatively noise-free
PPG. R values were calculated from the noise-free AC component and related to
SpaO2 by means of a conventional calibration curve.
It can thus be concluded that the performance of pulse oximeters in low per-
fusion scenarios varies widely between manufacturers and diﬀerent manufacturer
models. It does seem however, that the sensitivity and speciﬁcity of the so-called
`Generation 3' pulse oximeters have improved when compared to previous versions.
The measurement of SpaO2 in severe hypoperfusion scenarios is, however, still a ma-
jor issue, as all present time pulse oximeters need an AC (ie. pulsatile) component
in the PPG to calculate SpaO2.
3.4 Pulse Oximetry in Determining Venous
Saturation
The value of SvO2 measurement (mixed and central) in clinical monitoring is a
subject that has been discussed for many years. Claims have been made that SvO2
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is a good indicator of the oxygen supply-demand balance in the body (Kandel and
Aberman, 1983), while studies done by Reinhart and Bloos (2005) indicated that an
additional treatment of maintaining SvO2 levels in patients suﬀering from sepsis or
septic shock increases survival. SvO2 may also be useful for assessing patients with
peripheral vascular disease (Yoxall and Weindling, 1997). Three invasive types of
SvO2 measurement are used today, namely the use of an pulmonary artery catheter
(Kandel and Aberman, 1983), a central venous catheter (Reinhart et al., 1989)
or a venous blood gas sample, all with associated risks and disadvantages (Sise
et al., 1981). The main disadvantages of using a venous blood gas sample are its
intermittence and invasiveness. A need thus exists for a continuous and non-invasive
method of measuring SvO2.
Yoxall and Weindling (1997) and Yoxall and Weindling (1996) studied the non-
invasive measurement of SpvO2 in adults and neonates by using a venous occlusion
method. This method can not be classiﬁed as a pure pulse oximetry method, as
pulse waveforms were not used to calculate SpvO2. A pressure cuﬀ was inﬂated
around the subject's forearm at a pressure of 30 − 40 mmHg to induce occlusion
of venous drainage for a short period of time. This occlusion of venous drainage
caused a rise inHbO2 andHb concentrations as a result of increased venous volume.
SpvO2 was calculated, using the modiﬁed Beer-Lambert's Law (Elwell and Hebden,
1999), to calculateHbO2 concentration relative to total haemoglobin concentration.
Yoxall and Weindling (1996) reported a SpvO2 bias and precision of 4.3±2.6% for
neonates. Yoxall and Weindling (1997) reported a SpvO2 bias and precision of
4.7±4.05% for adults. The merits of venous occlusion methods are debatable, but
its intermittance still remains a drawback (Echiadis et al., 2007).
Chan et al. (2003) and Echiadis et al. (2007) conducted studies into a new
pulse oximetry system capable of continuously monitoring SpvO2. The system, as
described by Chan and Smith (2003), relies on pneumatically induced venous pul-
sations to calculate SpvO2 using conventional pulse oximetry methods. Pneumatic
pressure and an artiﬁcial pulsation frequency was chosen to minimize interference
with normal arterial pulsations. Chan et al. (2003) conducted a study into the per-
formance of the new system on recovering cardiac surgery patients, while Echiadis
et al. (2007) studied the system's performance on 23 subjects undergoing cardiac
surgery. Both studies were inconclusive, but adequate correlation with reference
systems was displayed to warrant further investigation.
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In a study done by Aoyagi (2003), a ﬁve wavelength pulse oximetry system,
capable of measuring SpvO2 was mentioned. This system relies on a combination of
conventional pulse oximeter theory and scattering theory as presented by Schuster
(1905). SpvO2 is to be calculated by means of artiﬁcially induced venous tremors
or pulsations. This is, however, still a conceptual system and no studies into the
system's performance could be found.
It can thus be concluded that the determination of SpvO2 has its merits and
that a successful pulse oximeter prototype capable of measuring SpvO2 would be a
valuable addition to modern ICU equipment. A number of prototypes have been
presented, although no conclusive evidence of accurate and repeatable performance
have been found.
Chapter 4
System Development
The artiﬁcial pulse oximeter (APO) system operates upon the principle of generat-
ing an artiﬁcial pulse in the tissue under consideration and using an adapted pulse
oximetry system to measure both arterial and venous blood oxygen saturation from
these pulses.
A list of system speciﬁcations was initially compiled to clarify the objectives of
the study. These were:
1. The ﬁnal commercial device should be a bed-side monitoring device.
2. The system should be able to non-invasively measure SpaO2 in adults, chil-
dren, infants and neonates.
3. Accurate and repeatable measurement of SpaO2 in low saturation scenarios is
desirable.
4. The system should be able to monitor SpaO2 in patients suﬀering from severe
peripheral hypoperfusion.
5. The system must be adaptable to diﬀerent parts of the body.
After a prototype was designed to meet the above mentioned objectives and
initial tests conducted to analyzed the prototype's performance, two additional
objectives were identiﬁed. These were:
1. To incorporate into the system design the capability to accurately and re-
peatably measure SvaO2.
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2. To evaluate the system's performance in monitoring SvaO2.
The development of the APO system can be broadly divided into ﬁve diﬀerent
stages, namely a numerical simulation of expected system behaviour, hardware
development, signal processing, in vitro calibration and in vivo validation.
4.1 Artiﬁcial Pulse Oximetry (APO)
As mentioned in Section 3.1, conventional pulse oximetry is entirely dependent on
the detection of an AC-component in the photoplethysmograph. In the absence of
an AC-component, or with the AC-component being very small in comparison with
the DC-component, the red to infrared ratio R tends to become unity, regardless
of the arterial blood oxygen saturation, SaO2. In commercial pulse oximeters, a
false, but constant, SaO2 value of approximately 85% would be indicated, resulting
in a lack of reliable information, which is often required for critically ill patients.
Taking these factors into account, commercial pulse oximeters cannot reliably be
used in severe hypoperfusion scenarios.
An alternative to conventional pulse oximetry was developed in this study. This
alternative, called artiﬁcial pulse oximetry, attempted to bypass the above men-
tioned issues in low perfusion scenarios. This method is based upon the generation
of a clearly detectable artiﬁcial pulse in the tissue under consideration. In normal
tissue, and even tissue suﬀering from low perfusion, a residential or non-pulsatile
blood volume is present in the circulatory system. With conventional pulse oxime-
try, the SO2 of this non-pulsatile or DC blood component cannot be measured, but
if pulsatile behaviour can be externally induced, normal pulse oximetry principles
can be applied to measure SO2.
The APO system is based upon a peristaltic induced artiﬁcial pulse in the tissue
under consideration. In our case this tissue would be an extended ﬁnger. This
peristaltic action is induced by a system of three inﬂatable tubes, much resembling
a conventional sphygmomanometer or blood pressure cuﬀ, around the ﬁnger. This
principle can be seen as Figure 4.1.
In Figure 4.1, the inﬂatable tubes encircles the ﬁnger and are inﬂated in a spec-
iﬁed sequence. In sequence one, the proximal tube is inﬂated, pushing residential
blood in the circulatory system toward the ﬁnger tip. The tube situated in the
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1 2
3
Figure 4.1: Peristaltic Action
middle of the the cuﬀ is inﬂated in sequence two, while the proximal tube is kept in
an inﬂated state. This forces the residential blood in the direction of the ﬁnger tip.
Pulse propagation is represented by the arrows in Figure 4.1 After this, the distal
tube is inﬂated in sequence three. Sequence three operates in the same principle
as sequence two, with both proximal tube kept in an inﬂated state, and serves to
further enhance the pulse amplitude. The timing of sequences one to three can
be modiﬁed in order to obtain a sharp, artiﬁcially induced, peak. As mentioned
earlier, having established clearly detectable pulsatile behaviour in the ﬁnger, con-
ventional pulse oximetry principles could now be applied to measure the SO2 of
the residual blood.
The blood oxygen saturation, SO2, of residential blood varies according to its
location in the circulatory system, e.g. arterial or venous circulation. In normal
transmittance pulse oximetry systems, the saturation diﬀerence between arterial
and venous blood is not important, as only arterial blood is seen as having pulsatile
behaviour. Jorgensen et al. (1995) reported on the independence of transmittance
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pulse oximetry to venous pulsatile behaviour in situations where the sensors is
properly positioned and attached. Any venous pulsatile behaviour is thus seen as
minimal and ignored. However, in the case of the APO, pulsatile behaviour is
induced in both arterial and venous circulation. The inﬂuence of venous blood
cannot be ignored in this case, as the transmittance of light is inﬂuenced by both
the arterial and venous pulses. If a normal transmittance pulse oximetry approach
was followed, the measured SaO2 would be too low as a result of the inﬂuence of
the much lower venous saturation, SvO2. A dual approach was thus followed to
take SvO2 into account as well.
Using the APO system, coordinated pulses are induced in both the arterial and
venous circulation. By processing the photoplethysmograph, a ratio R correspond-
ing to a mixed arterial and venous saturation can be calculated. This mixed arterial
and venous saturation, SmO2, is a linear combination of SaO2 and SvO2, according
to the following:
SmO2 = PaSaO2 + (1− Pa)SvO2 (4.1)
with Pa the arterial pulse volume fraction relating the pulse amplitudes in the
arterial and venous circulation. This pulse volume fraction is mainly dependent on
the volume of residual blood present in the arterial and venous circulation and the
compliance of the arteriole and venule walls. This relationship will be referred to
as the arterio-venous hypothesis in future and will be discussed in more detail in
Section 4.2.2.C.
Assuming that Pa is a known variable, Equation 4.1 requires that either SaO2
or SvO2 be known in order to calculate the unknown saturation. To calculate SvO2,
SaO2 would have to be known as a prerequisite. This value for SaO2 is obtained
by using a conventional pulse oximetry sensor on an unaﬀected or healthy site
such as a ﬁnger on the opposite hand or the forehead. In order to minimize the
discrepancies between SaO2 on the aﬀected and unaﬀected measurement sites, the
unaﬀected site was chosen to be either as close as possible to the aﬀected site or
to be on a symmetrically similar body part such as the left hand if the right hand
was aﬀected. In using this approach, it is assumed that SaO2 will be similar in
the aﬀected and unaﬀected sites, even in situations of low perfusion, as oxygen
diﬀusion mainly occurs at capillary level. In no perfusion states, it is possible
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that this assumption would not be accurate, as SaO2 would drop in the arterial
circulation during extended periods of tissue occlusion. This assumption would
however be valid in scenarios where it is known that a certain degree of perfusion
exists, such as in the case of medicinal leech treatment of ischaemia.
Using the APO system, it would thus be possible to measure SmO2, and derive
SaO2 and SvO2 from this measurement using Equation 4.1. Knowing these tissue
parameters, the physician might be able to make a more informed decision on the
status of the aﬀected tissue, with a normal SaO2 and spuriously high SvO2 being
indicative of extended tissue damage.
4.2 System Simulation
A system simulation was conducted to verify whether the APO system would the-
oretically behave as expected, while also providing information on scenarios that
could not be approximated in an in vitro or in vivo experiment. The simulation
would also provide information on scenarios where experimental results were not
as expected. Various simulations of conventional pulse oximeter systems have been
conducted, but as far as the author could determine, none have made provision for
the venous pulsations inherent to the APO system's operation.
4.2.1 Simulation Techniques
Earlier qualitative simulations were based on Beer-Lambert's Law, which describes
tissue-photon interaction in a purely absorptive medium, while neglecting scatter-
ing. These simulations were soon upgraded to include scattering by introducing a
factor, called the diﬀerential pathway factor (DPF), to provide for the increase in
photon travel path, and an additive factor to provide for scattering losses as well
(Elwell and Hebden, 1999). These simulations however, show signiﬁcant deviation
from calibration curves used for commercial pulse oximeters (Schmitt, 1991).
Photon diﬀusion theory has also been successfully used to model the propa-
gation of light through biological mediums (Steinke and Shepherd, 1988; Schmitt
et al., 1990; Schmitt, 1991). Biological mediums are generally characterized by a
high optical depth and short mean free path, making it well-suited to diﬀusion the-
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ory modeling. Good correlation with commercial pulse oximeter curves have been
shown by (Schmitt, 1991).
More recently, Monte Carlo simulations have been utilized to model the random
behaviour of tissue-photon interactions due to the inherently random nature of
multiple scattering events. The Monte Carlo method tracks the path of singular
photons through the optical medium and calculates the probability of the photon
emerging at a point and direction of interest. As singular photons are tracked and
large numbers of photon enter the optical medium, considerable computation time
is needed (Hiraoka et al., 1993).
It was decided to model the light propagating properties of the ﬁnger tissue
using photon diﬀusion theory, based on the reported correlation with existing pulse
oximeter calibration curves, as well as the relative ease with which the governing
equations could be adapted to provide for venous pulsations.
4.2.2 Photon Diﬀusion Theory
Photon diﬀusion theory approximates photon propagation through a medium as a
diﬀusive process. As mentioned earlier, tissue is well suited to diﬀusive modelling
as a result of a high optical depth and short mean free path. A short mean free
path is an important prerequisite for diﬀusion modelling as predominantly scat-
tering behaviour is assumed over absorption. In addition to this, it is assumed
that scattering from a unit volume of tissue is isotropic. Although scattering in
biological mediums is generally highly anisotropic, isotropic scattering can be as-
sumed if the optical constants are adapted to account for highly forward scattering
behaviour and if boundary conditions for the diﬀusion solution is appropriately
chosen (Schmitt et al., 1990).
4.2.2.A Conventional Photon Diﬀusion Model
The governing equation which describes photon propagation as a diﬀusive process,
1
ρ2
d
dρ
(
ρ2
dψ(ρ)
dρ
)
− α2ψ(ρ) = − 1
D
S(ρ) (4.2)
was derived by Schmitt (1991) using an angle-independent solution of the gen-
eral transport equation. In Equation 4.2, ρ [mm] is the physical distance from the
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photon source, ψ(ρ) and S(ρ) are the scalar photon density and source function,
respectively, at point ρ, α [mm−0.5] is the attenuation coeﬃcient and D [mm] is
the diﬀusion coeﬃcient. α and D can be described in terms of the bulk absorption
coeﬃcient Σab [mm
−1] and the transport corrected bulk scattering coeﬃcient Σ′s
[mm−1] as follows (Schmitt, 1991):
α =
√
3Σab(Σ′s + Σab) (4.3)
D =
1
3(Σ′s + Σab)
(4.4)
The bulk absorption and scattering coeﬃcients will be discussed in the following
section.
From the subsequent solution of Equation 4.2 by Schmitt (1991), blood oxygen
saturation SaO2 was related to the red/infrared ratio R through the following:
SaO2 =
Rσ0%ab,ir −K ′tσ0%ab,r
K ′t(σ
100%
ab,r − σ0%ab,r) +R(σ0%ab,ir − σ100%ab,ir )
(4.5)
with
K ′t =
Σ′s,r
(
αrd−1
α2rd
)
Σ′s,ir
(
αird−1
α2ird
) (4.6)
where σ0%ab,r [um
2] and σ100%ab,r [um
2] are the optical absorbtion cross-sections for
red blood cells (RBCs) containing totally deoxygenated and oxygenated haemoglobin,
respectively. A subscript r or ir indicates an optical property at the lower red wave-
length (r) or higher infrared wavelength (ir). Optical absorption cross-sections will
be discussed in Section 4.2.2.B. In Equation 4.6, d [mm] is the ﬁnger diameter.
Results for this approach will be discussed in Section 5.1.
4.2.2.B Bulk Absorption and Scattering Coeﬃcients
As can be noted from Equations 4.3 to 4.6, diﬀusive photon propagation properties
in biological mediums can be entirely described in terms of the bulk absorption
coeﬃcient Σab [mm
−1] and the transport corrected scattering coeﬃcient Σ′s [mm
−1]
of the tissue. The transport corrected scattering coeﬃcient is derived from the
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isotropic scattering coeﬃcient to account for the highly forward scattering charac-
teristics of tissue.
The bulk absorption coeﬃcient Σab [mm
−1] in Equation 4.3 can be seen as a
cumulative function of the absorption coeﬃcients of oxygenated and deoxygenated
blood, Σartab [mm
−1] and Σvenab [mm
−1] respectively, as well as that of blood perfused
tissue Σtisab [mm
−1]. This function can be formulated as follows (Schmitt, 1991):
Σab = VaΣ
art
ab + VvΣ
ven
ab + [1− (Va + Vv)] Σtisab (4.7)
with Va and Vv the respective volume fractions of resident oxygenated and de-
oxygenated blood in the tissue.
The absorption coeﬃcient for whole blood in Equation 4.7 is a function of
hematocrit H, RBC volume υi [cm
3], fractional arterial or venous blood oxygen
saturation SaO2 or SvO2 and the optical absorption cross sections for an single
RBC, σ0%ab [um
2] and σ100%ab [um
2]. These relationships were stated by Schmitt
(1991) as:
Σartab =
H
υi
[
SaO2σ
100%
ab + (1− SaO2)σ0%ab
]
(4.8)
Σvenab =
H
υi
[
SvO2σ
100%
ab + (1− SvO2)σ0%ab
]
(4.9)
The H
υi
factor at the beginning of Equations 4.8 and 4.9 scales the optical cross
sections to the macroscopic coeﬃcients for whole blood. Alternative scaling factors
have been proposed, but according to Faber et al. (2004) good correlation with
experimental data were obtained through the use of the H
υi
scaling factor.
The optical cross sections for a particle, as used in Equations 4.8 and 4.9,
can be deﬁned as the total absorbed or scattered power, divided by the incident
power ﬂux density (Steinke and Shepherd, 1988). The absorption cross section
for an RBC was approximated by a Mie theory approximation which provides
exact solutions to Maxwell's equations. Mie algorithms provided by Michel (2007)
were used to calculate σab for a singular RBC. By geometrically approximating the
irregular shape of an RBC with the homogeneous spherical particle Mie model,
this inherently remains an approximation, but good correlation between calculated
and experimental values for σab were reported by Reynolds et al. (1974, 1976) and
Pierce (1972) for a spherical particle with a volume equal to that of an RBC.
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As inputs to the algorithms provided by Michel (2007), the complex index of
refraction n(λ) = n(λ) + iκ(λ) for a singular RBC and the index of refraction for
blood plasma were needed. The index of refraction for blood plasma used in the
Mie calculations was taken as 1,35 (Gonchukov et al., 2000; Lu et al., 2005). The
complex index of refraction for an RBC is directly proportional to the absorption
coeﬃcients of haemoglobin at a speciﬁc wavelength of light. The complex part of
n(λ), iκ(λ) relates to the molar extinction coeﬃcient of HbO2 or Hb through the
following relationship (Hammer et al., 1998):
κ(λ) =
ln10
4pi
xλ [me(λ)] (4.10)
with with x the concentration of haemoglobin (335 g/L), me(λ) [cm−1M−1]
the molar extinction coeﬃcient of HbO2 or Hb at the vacuum wavelength λ [cm].
Molar extinction coeﬃcient values were obtained from Prahl (1998). The real part
of n(λ), n(λ) was derived by Friebel and Meinke (2006) using Fresnel reﬂectance
measurements on haemoglobin solutions obtained by haemolysing human RBCs.
The following relationship was used:
n(λ) = nwater(λ) [β(λ)x+ 1] (4.11)
with nwater(λ) the wavelength dependent refractive index of water and β(λ)
the wavelength dependent refractive increment as provided by Friebel and Meinke
(2006). This relationship does not take eﬀect of haemoglobin saturation into ac-
count. Values for n(λ) obtained by Faber et al. (2004) take this eﬀect into account,
but unfortunately the values stated are for haemoglobin concentrations other than
those used in the context of this study. These values, however, do show an approx-
imately constant diﬀerence between oxygenated and deoxygenated haemoglobin
solutions. This diﬀerence was used to modify n(λ) according to haemoglobin oxy-
genation. The complex indices of refraction and absorption cross-sections of an
RBC containing HbO2 and Hb at the wavelengths of interest are shown in Ta-
ble 4.1. These values are in good agreement with those provided by Meinke et al.
(2007) and Schmitt et al. (1986).
Values for the absorption coeﬃcient of bloodless tissue Σtisab [mm
−1] in Equa-
tion 4.7 were found using the approximations as stated by Jacques (1998). The
total absorption coeﬃcient for bloodless tissue can be seen as a cumulative function
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Table 4.1: Complex Indices of Refraction and Absorption Cross-Sections
(λ) HbO2 Hb
Index of Absorption Index of Absorption
Refraction Cross-section Refraction Cross-section
660 1.4179 + i1.948e−5 0.03668 1.4129 + i1.967e−4 0.36528
740 1.4159 + i3.048e−5 0.05102 1.4109 + i7.626e−5 0.12656
880 1.4148 + i9.378e−5 0.13149 1.4098 + i5.904e−5 0.08231
910 1.4154 + i1.02e−4 0.13837 1.4104 + i6.509e−5 0.08780
940 1.4155 + i1.054e−4 0.13843 1.4105 + i6.012e−5 0.07852
of the absorption coeﬃcients of the epidermis Σepiab , dermis Σ
der
ab and subcutaneous
tissue or subdermis Σsderab . In all tissue layers, the absorption coeﬃcient is a func-
tion of the wavelength of light used. The total absorption coeﬃcient for bloodless
tissue Σtisab [mm
−1] was thus approximated as follows:
Σtisab = cepiΣ
epi
ab + cderΣ
der
ab + (1− cepi − cder)Σsdera [cm−1] (4.12)
with cepi and cder the cross-sectional fraction of the ﬁnger diameter occupied by
the epidermis and dermis, respectively.
The eﬀect of the epidermal absorption coeﬃcient Σepiab [mm
−1] in Equation 4.12
can be seen as a combination between baseline skin absorption and absorption due
to melanin. Melanin is a polymer found in melanosomes, particles found in varying
concentrations in the epidermis. Diﬀering melanosome concentrations are the main
reason behind diﬀerences in skin colour. Melanosome fractions can be seen below
as Table 4.2 for diﬀerent skin colours (Jacques, 1998).
Table 4.2: Melanosome Fraction
Skin Colour Melanosome Fraction
Light 0.013-0.063
Moderate 0.11-0.16
Dark 0.18-0.43
The overall epidermal absorption coeﬃcient Σepiab [cm
−1], as used in Equation 4.12,
can be found as deﬁned by Jacques (1998):
Σepiab = FΣ
mel
ab + (1− F )Σebab (4.13)
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with F the melanosome volume fraction as found in Table 4.2, Σebab the baseline
epidermal absorption coeﬃcient and Σmelab the absorption coeﬃcient due to melanin
absorption.
The baseline epidermal absorption coeﬃcient Σebab [cm
−1] in Equation 4.13 is
deﬁned by Jacques (1998) as follows:
Σebab = 0.244 + 85.3e
−(λ−154)
66.2 (4.14)
with λ the wavelength [nm] used. This approximation was empirically derived
using bloodless rat skin due the similarities to neonatal skin.
The melanin induced absorption coeﬃcient Σmelab [cm
−1] from a single melanosome,
as used in Equation 4.13 is obtained from Jacques (1998).
Σmelab = 6.6e
−11λ−3.33 (4.15)
As this only provides a coeﬃcient for a single melanosome, a multiplying factor
had to be included in the calculation of overall Σepiab [mm
−1] to account for the
amount of melanosomes per unit volume of epidermis. It has to be noted that
the melanin content of melanosomes diﬀers in varying degrees between individuals,
causing this expression to be viewed as a general approximation at best.
The dermal and subdermal absorptive coeﬃcients, Σderab [mm
−1] and Σsderab [mm
−1],
as used in Equation 4.12, was approximated by Simpson et al. (1998) using an
inverse Monte Carlo simulation on diﬀuse reﬂectance and transmittance single in-
tegrating sphere measurements on ex vivo human skin.
The transport-corrected scattering coeﬃcient Σ′s [mm
−1] for blood-perfused tis-
sue can be expressed as a cumulative function of the coeﬃcients of the major scat-
tering components. Σ′s, as used in Equation 4.3 was expressed by Schmitt (1991)
as follows:
Σ′s = (Va + Vv)Σ
′b
s + [1− (Va + Vv)] Σ
′tis
s (4.16)
with Σ
′b
s [mm
−1] and Σ
′tis
s [mm
−1] the transport corrected scattering coeﬃcient
for blood and tissue, respectively. Σ
′tis
s is the representative coeﬃcient of Mie
and Raleigh scattering caused by epidermal, dermal and subdermal tissue compo-
nents. Raleigh scattering is scattering caused by particles much smaller than the
wavelength of incident light, such as cellular structures, while Mie scattering is
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scattering caused by particles with diameters the same order of magnitude as the
incident wavelength, such as large collagen ﬁbers (Jacques, 1998)
Various approaches exist for calculating Σ
′b
s as used in Equation 4.16. Steinke
and Shepherd (1988) calculated Σ
′b
s by using a spherical particle Mie scattering
approach to calculate the scattering cross-section σs of a singular RBC, as well as
the anisotropy factor g. The anisotropy factor g can be deﬁned as the mean cosine
of the scattering angle. This factor is an indication of the scattering behaviour
of the medium, with g ≈ 1 indicating highly forward scattering behaviour and g
<< 1 indicating highly back scattering behaviour. Σ
′b
s was obtained by adapting
σs with a (1-g) factor to account for the highly forward scattering nature of blood
and a factor dependent on hematocrit H and RBC volume υi. Good correlation
with experimental values has been found for σs (Reynolds et al., 1974, 1976), but
experiments have shown that Mie theory signiﬁcantly overestimates the true g
value. This signiﬁcance is due to the fact that even small variations in the value
of g result in large variation in the (1-g) factor as the (1-g) factor is small. The
discrepancy between experimental and Mie values for g is a result of the lesser
forward peaked scattering function, inherent to randomly orientated, non-spherical
particles such as RBCs, than that of the volume equivalent spherical particles used
for the Mie approximation (Lovell et al., 1999). It was thus decided to rather use
the approach followed by Meinke et al. (2007) who determined empirical functions
to model the hematocrit and suspending medium dependence of Σ
′b
s directly. In
this approach, Σ
′b
s for RBCs in blood plasma is related to the transport corrected
scattering coeﬃcient for RBCs suspended in a saline solution. This coeﬃcient Σ
′sa
s
[mm−1] can be expressed as follows:
Σ
′sa
s = 0.1167Σ
′
sST (λ)H (4.17)
with Σ′sST (λ) [mm
−1] the wavelength dependent scattering coeﬃcient for a stan-
dardized saline RBC suspension as provided by Meinke et al. (2007). This value for
Σ
′sa
s was adapted to Σ
′b
s by reducing the original value by the recommended 35% in
the 60 0− 1 100 nm wavelength range, as noted by Meinke et al. (2007) for blood
plasma RBC suspensions.
As noted earlier, Σ
′tis
s in Equation 4.16 is a function of scattering coeﬃcients as
a result of Mie and Raleigh scattering. Due to the thinness of the epidermis and
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similarity between scattering coeﬃcients for the epidermis and dermis, Σ
′tis
s can be
seen as a combination of the transport corrected scattering coeﬃcients of just the
dermis and subdermis, Σ
′der
s [mm
−1] and Σ
′sder
s [mm
−1]. Values for Σ
′der
s and Σ
′sder
s
were obtained from Simpson et al. (1998). An expression for Σ
′tis
s [mm
−1] can be
found below.
Σ
′tis
s = CderΣ
′der
s + (1− Cder)Σ
′sder
s [cm
−1] (4.18)
In Equation 4.18, cder is the same ﬁnger diameter fraction as used in Equa-
tion 4.12.
The bulk absorption and scattering properties of whole blood, bloodless tissue
and blood perfused tissue for all wavelengths of interest can be seen below as
Table 4.3.
Table 4.3: Absorption and Scattering Properties
Wavelength 660 nm 740 nm 880 nm 910 nm 940 nm
Property [mm−1] Equation
Σartab @ 100% SaO2 4.8 0.183 0.256 0.657 0.692 0.692
Σartab @ 50% SaO2 4.8 1.005 0.444 0.535 0.565 0.542
Σartab @ 0% SaO2 4.8 1.826 0.633 0.412 0.439 0.393
Σ
′b
s 4.17 1.536 1.441 1.410 1.393 1.444
Σtisab 4.12 0.015 0.012 0.011 0.015 0.018
Σ
′tis
s 4.18 1.617 1.447 1.259 1.239 1.227
Σab @ 100% SaO2 4.7 0.049 0.040 0.073 0.080 0.082
Σab @ 50% SaO2 4.7 0.132 0.059 0.061 0.067 0.067
Σab @ 0% SaO2 4.7 0.197 0.074 0.051 0.057 0.073
Σ′s 4.16 1.609 1.447 1.274 1.254 1.249
Constants used: H=0.45, Va=Vv=0.05, υi=90 um3, D=8,4 mm, Epidermal Thickness=60 um,
Dermal Thickness=1,2 mm, Arteriovenous Saturation ∆=10%
4.2.2.C Photon Diﬀusion Theory for Arterial and Venous Pulsations
As mentioned earlier, all previous photon diﬀusion theory simulations found by
the author, only took the arterial pulsatile component into consideration when
simulating the relationship between R and arterial blood oxygen saturation SaO2.
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This is normally a valid approach as the small diameter capillaries in the capillary
bed reduces the arterial systolic pulses to an acceptably low value in the venous
circulation. Even if there is a venous pulsatile component, the inﬂuence on the
peak-to-trough values, as obtained from the PPG, should be negligibly small.
Using this approach, Schmitt (1991) derived the relationship between R and
SaO2 by assuming that the AC component in the PPG is caused by the inﬂux
of arterial blood during systole, resulting in an increase in the bulk absorption
coeﬃcient of the blood perfused tissue. This increase in Σab was expressed as
follows:
Σab + ∆Σab = (Va + ∆Va)Σ
art
ab + VvΣ
ven
ab + [1− (Va + ∆Va + Vv)] Σtisab (4.19)
with ∆Va the inﬂux of arterial blood during systole. The AC component caused
by the increase in the bulk scattering coeﬃcient of the blood perfused tissue was
neglected due to the similarity between Σ
′b
s at the red and infrared wavelength.
This scattering AC component only results in a DC oﬀset of the absorption AC
component in the PPG. By assuming that Σartab >> Σ
tis
ab , as can be noted from
Table 4.3, Schmitt (1991) concluded the following:
∆Σab = ∆VabΣ
art
a (4.20)
Using Equation 4.20, Schmitt (1991) derived Equation 4.5.
In the case of the APO, the assumption of a non-important venous pulsatile
component can not be validated. As blood is pushed into the measurement zone
via peristalsis, both arterial and venous absorption contributes toward the AC
component in the PPG. If the venous pulsatile component is ignored in this scenario,
the ratio, and thus arterial saturation, calculated would indicate a lower value that
is in fact the case. This is as a result of the much lower saturation in the venous
circulation. The SaO2 would thus be a mixture of arterial and venous saturation,
resulting from the averaged value being calculated.
This eﬀect was taken into account by modifying Equation 4.19 to include the
eﬀect of venous pulsatile blood. By including a ∆Vv factor to account for the inﬂux
of venous blood into the measurement zone, Equation 4.19 becomes,
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Σab + ∆Σab = (Va + ∆Va)Σ
art
ab + (Vv + ∆Vv)Σ
ven
ab
+ [1− (Va + ∆Va + Vv + ∆Vv)] Σtisab (4.21)
so that,
∆Σab = ∆Va(Σ
art
ab − Σtisab ) + ∆Vv(Σvenab − Σtisab ) (4.22)
If it is assumed that Σartab and Σ
ven
ab >> Σ
tis
ab , it can be concluded that
∆Σab ≈ ∆VaΣartab + ∆VvΣvenab (4.23)
Using the same approach as Schmitt (1991) to obtain Equation 4.5, ratio R can
now be expressed as
R = K ′t
Σartab,r∆Va + Σ
ven
ab,r∆Vv
Σartab,ir∆Va + Σ
ven
ab,ir∆Vv
(4.24)
with K ′t calculated using Equation 4.6.
The relationship between ∆Va and ∆Vv was needed to obtain a solution to
Equation 4.24. This relationship was obtained by comparing arterial and venous
compliance, with compliance being the change in volume for a given change in
pressure. If it is assumed that the APG generates an equal pressure wave in both the
arterial and venous circulation, compliance would determine the magnitude of ∆Va
and ∆Vv. In vivo compliance is not a static property, but is in fact a very dynamic
property due to the autonomic reﬂexes responsible for blood pressure regulation
(Jagomagi et al., 2005; Martini and Bartholomew, 2003). Due to this and the
wide variation in compliance values recorded in literature for arterial and venous
compliance (Jagomagi et al., 2005; Kawarada et al., 1988; Krenz and Dawson,
2003), universal arterial and venous compliance values could not be established.
It was thus decided to model the arterial-to-venous compliance ratio as 1:1 as a
ﬁrst approximation. This ratio could easily be revised if the results indicated that
compliance had a major eﬀect on R values. Using this compliance ratio, R could
be expressed in terms of SaO2 and SvO2 as follows:
R = K ′t
SaO2(σ
100%
ab,r − σ0%ab,r) + SvO2(σ100%ab,r − σ0%ab,r) + 2σ0%ab,r
SaO2(σ
100%
ab,ir − σ0%ab,ir) + SvO2(σ100%ab,ir − σ0%ab,ir) + 2σ0%ab,ir
(4.25)
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By stating SaO2 as a constant and specifying SvO2 as values ranging from 0%
to 100%, R could thus be calculated. Results for this approach will be discussed in
Section 5.1.
4.3 Hardware Development
The hardware development phase consisted of the design and integration of several
subsystems. These systems were: the optical components, the A/D converter and
optical driver and the artiﬁcial pulse generator (APG). An integrated representation
of these systems can be seen as Figure 4.2. The software system shown in Figure 4.2
will be discussed in Section 4.4.2.
                                              
                                             
NIRS Optical
Hardware
Data
Acquisition
System
PC
Graphical
Data Display
User Interface Artificial Pulse 
Generator
Figure 4.2: Overall APO System
In Figure 4.2, the NIRS hardware comprises of the LEDs that transmits the
light through the ﬁnger to the photosensitive detector. The data-acquisition system
comprises of the A/D converter and optical components driver.
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4.3.1 Optical Components
The optical components of the APO system consist of two sensors, both consisting
of a dual-wavelength LED assembly and the highly sensitive silicon photosensitive
detector. The basic hardware structure that was used was that of a disposable pulse
oximetry sensor as provided by Nonin Medical, Inc., the PurelightTM 7000A. The
optical components of one of these sensors had to be modiﬁed to satisfy the low
saturation system speciﬁcations, as stated earlier. These modiﬁcations entailed re-
placing the sensor LEDs with LEDs speciﬁcally suited to the measurement scenario.
The other sensor, to be used in the unaﬀected tissue, high saturation scenario, was
used with its original optical components.
The sensitivity and accuracy of pulse oximetry is highly reliant on the combi-
nation of LEDs used in the sensor design. In conventional pulse oximetry systems,
the wavelengths of the two LEDs are chosen as to maximize the sensitivity of the
sensor. This is achieved by choosing at least one of the wavelengths in a band where
the diﬀerence in absorption coeﬃcient for Hb and HbO2 is notable (Mannheimer
et al., 1997). Absorption coeﬃcients for Hb and HbO2 can be seen in Figure 3.2.
Commercial sensors usually employ a 660 nm (red) LED and a second LED in the
880-910 nm band or near to 940 nm.
Unfortunately, this combination is only suited to measuring saturation values in
excess of 70%. Below this value, accuracy deteriorates drastically. Schmitt (1991)
postulates that accuracy is aﬀected by ampliﬁed variance in unbalanced multiple
scattering eﬀects caused by normal variations in physiological parameters such as
residual blood volume, arteriovenous saturation diﬀerence and ﬁnger diameter.
This accuracy deﬁciency was addressed by utilizing light wavelengths other than
those used in commercial sensors. These wavelengths were speciﬁcally chosen to
improve accuracy at low saturations. The choice was based upon the work of
Mannheimer et al. (1997), who tried to optimize accuracy at low saturations by
matching perturbations in photon pathlength at the two wavelengths caused by
physiological variations. Additionally, it was attempted to match the penetration
depths of the two wavelengths to minimize the eﬀects of tissue heterogeneity. After
animal veriﬁcation, it was concluded that a 735/890 nm LED combination would
perform best in low saturation scenarios (Mannheimer et al., 1997).
The new LEDs used in the design of the modiﬁed sensor were of the wavelengths
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740 nm and 880 nm. The datasheets of these LEDs, ELS-740-994 and ELS-880-
894-3, as supplied by Epigap Optoelektronik GmbH, can be found in Appendix A.
Precise matches for the wavelengths required, could not be obtained, but the inﬂu-
ence of the small wavelength discrepancies was assumed to be negligible. Although
suited to low saturation value measurements, this combination has the negative
eﬀect of reducing sensor sensitivity drastically, resulting in small variations in R
causing big variations in measured saturation values. This eﬀect can be seen in the
in vitro calibration curves, presented in Section 5.2. In selecting the above men-
tioned LEDs, three factors were considered, namely peak forward current, viewing
angle and availability. As can be seen from Appendix A, the ﬁrst two factors com-
pared well for the selected LEDs. Ideally, selection would have been based upon
radiant intensity as well, but values for this parameter were not provided for the
available LEDs. The approach followed in this study thus assumed that intensity
discrepancies would have a negligible eﬀect on sensor performance. This assump-
tion was based upon the possibility that the in vitro calibration would inherently
compensate for the eﬀects of an intensity mismatch.
The original LEDs, as used in the sensor for the unaﬀected tissue, were in
the form of a dual wavelength LED of the wavelengths 660 nm and 910 nm. As
explained earlier, this original combination is well-suited for a high sensitivity setup
to measure saturation values in the range above 70%.
The photosensitive detectors, as supplied in the original sensors, were used in
both prototypes. Two sensors were thus available for use in diﬀerent scenarios,
namely a highly sensitive 660/910 nm wavelength combination for use in high sat-
uration scenarios and a less sensitive 740/880 nm wavelength combination for use
in low saturation scenarios.
4.3.2 A/D Converter and Optical Driver
The analogue-to-digital (A/D) converter and optical driver system was designed as
a combined system that is compatible with the Nonin PurelightTM 7000A sensor,
as mentioned in Section 4.3.1. The A/D converter converts and transmits the
analog sensor PPG output, as produced by the photodetector, as the digital output
needed by the PC. The optical driver drives the dual wavelength LED assembly at
a speciﬁed duty cycle and emitting strength. The A/D converter and optical driver
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system, as designed by GeoAxon (Pty.) Ltd., can be seen in Appendix B. Only
this system was used as originally designed by another party, all other modiﬁcations
and design were done by the author.
In Figures B.1 and B.2, the photodiode ampliﬁer and A/D converter base is re-
sponsible for the microcontroller unit (MCU) and sensor integration. The analogue
photodetector output is typically very small and needs to be ampliﬁed before A/D
conversion. This variable gain ampliﬁcation is done through the use of CD4053BC
multiplexers and TLC2264 operational ampliﬁers. Ampliﬁer gain is controlled by
the MCU by means of ports PDA-SW-A to C and ports ADC-SW-A and B. Port
CCP in Figure B.2 transmits the ampliﬁed sensor output to the MCU.
The power supply unit (PSU) in Figure B.3 consists of positive and negative
voltage regulators, REG71050 and MAX889T, respectively. These regulators are
responsible for the speciﬁed supply voltages as needed for the CD4053BC multi-
plexers. Power supply to these regulators is maintained via the USB port, in the
form of port V-BUS.
A/D conversion is conducted in the MCU, as shown in Figure B.4. This sys-
tem comprises mainly of a 18-bit PIC18F252 microcontroller, responsible for A/D
conversion, photodiode ampliﬁer gain regulation and LED control. The ampliﬁed
sensor output, received via port CCP, is converted to a 16-bit digital represen-
tation and transmitted to the USB universal asynchronous receiver/transmitter
(USB UART) unit via port TXD. The USB UART can be seen in Figure B.5. As
mentioned earlier, photodiode ampliﬁer gain is controlled via ports PDA-SW-A
to C and ports ADC-SW-A and B. The dual LED assembly is directly driven by
the MCU in a bridge conﬁguration at a frequency of 50 Hz, with a measured 1%
duty cycle and Von = 4,4 V. Six output ports on the microcontroller have been
connected in parallel to source the needed LED driving current for the speciﬁed
emitting strength.
The USB UART is responsible for the transmittance of serial data to the PC
via the USB port. This data transfer occurs using the communication setup as
speciﬁed in Table 4.4.
In adapting the LEDs of the sensor, resistor R13 in Appendix B.4 had to be
replaced to limit the current through the LEDs. Peak forward current for both
LEDs is speciﬁed as 100 mA and peak pin source current for the microcontroller
as 25 mA. This translated into a combined peak source current of 150 mA for the
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Table 4.4: USB UART Communication Setup
Parameter Setting
Baud Rate 38400
Data Bits 8
Stop Bits 1
Parity None
Flow Control Hardware Controlled
microcontroller. The LED peak forward current was thus the limiting factor and
resistor R13 was replaced with a 51 Ω resistor to limit the current to (4.4/51) =
86 mA.
4.3.3 Artiﬁcial Pulse Generator (APG)
The artiﬁcial pulse generator (APG) forms the basis upon which this form of low
perfusion oximetry rests. By inducing an artiﬁcial blood pulse in occluded or nearly
occluded tissue, non-invasive pulse oximetry principles can be used to measure
blood oxygen saturation. The APG consists of three subsystems, namely, the
pneumatic pressure generator, electronic control system and pressure cuﬀ. A basic
layout of the APG can be seen below as Figure 4.3.
Electronic Control System
PC
Pressure Control Electronics
Pulse
Control
Electronics
USB
Pneumatic Pressure 
Generator
Pressure Cuff 
3 Compressed
Air Lines
Figure 4.3: APG Layout
The pneumatic pressure generator was responsible for maintaining and sup-
plying compressed air at a pressure of 600 mmHg. This pressure was chosen to
ensure that cuﬀ pressure suﬃciently exceeds the normal systolic blood pressure of
120 mmHg and thus to ensure that a deﬁnite arterial pulse is generated in the af-
fected tissue. A pressure slightly higher than systolic would normally be suﬃcient,
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but due to the design of the pressure cuﬀ, a much higher pressure had to be used.
These design eﬀects will be discussed in more detail in Section 5.4. The pneumatic
setup and prototype can be seen as Figures 4.4 and 4.5, respectively. A dual com-
pressor setup was used to ensure the correct air supply-demand balance, because
the QJT-27QB compressor, as supplied by Mantech Electronics, can only supply
1,3 l/min, which is less than the required ﬂow rate. The accumulator was included
to minimize the decrease in system pressure in high demand scenarios. The ﬂow
regulators were included to control the inﬂation speed of the pressure cuﬀ. Uncon-
trolled inﬂation could rupture a tube in the pressure cuﬀ. All components, except
the compressors, were standard components, supplied by Festo. Catalog numbers
for all the components can be found in Appendix C.
Compressor
Non-Return Valve
Air Collector
Pressure Gauge
PC Controlled 5/8
Valve Bank
Flow Regulator
Output Ports to Pressure Cuff
Non-Return Valve
Compressor
Figure 4.4: Pressure Generator
As can be seen from Figure 4.3, the electronic control system consists of two
separate subsystems, namely, the PC-based pulse control system and the pressure
control system. The pulse control system controls the pulse number, sequence, fre-
quency and duty cycle, whilst the pressure control system regulates overall system
pressure.
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Figure 4.5: APG Prototype
The pulse control system consists of a Matlab based user interface to specify
control parameters, a data acquisition module to generate hardware control outputs
and output ampliﬁcation hardware to control the solenoid-valve assembly. The
Matlab based user interface will be discussed in Section 4.4.2.
A National Instruments USB-6218 data acquisition module (DAQ), was used
to generate the control outputs according to the user speciﬁed control parameters.
This module's digital output options and availability made it well-suited for this
purpose, although it was not the most elegant solution. The active control output
was a logic high to activate the solenoid controlled valve and to allow air to ﬂow
into the pressure cuﬀ. The spring-loaded valve stopped air ﬂow automatically in
the event of a logic low output level.
The USB-6218 DAQ is only capable of sourcing a maximum output current of
16 mA at a logic high output of 3,7 V (National Instruments Technical Communi-
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cations, 2006). Since the MSFG-24DC/42AC solenoid coils require a operating DC
voltage of 24 V and source current of 188 mA (Festo Technical Communications,
2004), the DAQ would not be able to directly drive the coils. Output ampliﬁcation
hardware had to be included to achieve this. This hardware consisted of a voltage
regulator, power ampliﬁer and power relay. The voltage regulator was needed to
convert the available 12 VDC to the 6 VDC needed by the power ampliﬁer. The
power ampliﬁer was included to source the current needed to control the power
relays, which in turn would switch the solenoid coils. A circuit diagram of the
combined voltage regulator, power ampliﬁer and relay can be seen in Figure B.6.
As can be seen from Figure B.6, a LM317 3-terminal adjustable regulator from
Texas Instruments was used as a positive voltage regulator. The regulator cir-
cuit was provided by Fairchild Semiconductor Technical Communications (2005).
Resistance values for R1 and R2 were calculated using the relationship
Vo = 1.25
(
1 +
R2
R1
)
(4.26)
with Vo = 6 V. Values for C1 and C3 were obtained from Fairchild Semicon-
ductor Technical Communications (2005). Capacitor C1 was included to prevent
ripple ampliﬁcation as the output voltage was raised. Regulator oscillation eﬀects
were reduced by including capacitor C2 into the design.
The power ampliﬁer, as seen in Figure B.6, was designed using a LM324 op-
erational ampliﬁer to drive a 2N222 BJT transistor. By utilizing this setup, the
transistor was used to deliver the needed switching current to the power relay. The
FRS1-S power relay from Mantech Electronics was used to connect the solenoid
coil to the 24 VDC it needs in its active state. Resistor R3 was included as current
limiter, while capacitor C3 was included as default protection against supply ripple.
The pressure control system operated on the so-called `bang-bang' control prin-
ciple. By constantly comparing system pressure to a ﬁxed set point, the compressors
were either switched fully on or oﬀ. The compressors were switched on as soon as
system pressure decreased below 0,78 bar and were switched oﬀ as soon as system
pressure increased above 0,8 bar. This control principle was employed due to the
need to minimize the time to return to the speciﬁed pressure. System pressure was
monitored using a SDE1 pressure sensor from Festo, as can be seen in Figure 4.6
and Appendix C. Overvoltage protection was included in the form of a 4 A fuse.
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The SDE1 uses a PNP output to provide a logic high output of 24 V if the pressure
drops below the set point. Maximum output current for this pressure sensor is
speciﬁed as 120 mA, eliminating the possibility of directly driving the compressors,
as each QJT-27QB compressor draws a nominal current of 250 mA. A FRS1-S
power relay was used to drive the compressor, with the control circuit connected
to the SDE1, as shown in Figure B.7. Resistor R1 was included to limit the SDE1
output current to 50 mA.
Figure 4.6: APG Pressure Control
The pressure cuﬀ was responsible for inducing the artiﬁcial pulse by inﬂating a
system of tubes around the ﬁnger. Pressure exerted by the cuﬀ was used to push
residual blood into the area of interest. The cuﬀ operated on the same principle
as a conventional sphygmomanometer used to measure blood pressure. The cuﬀ
consisted of three separately inﬂatable, expandable tubes, each with an independent
air supply. The inﬂatable tubes were contained in a fabric enclosure that would
not yield under pressure. To account for patient variability, the deﬂated cuﬀ was
designed to wrap around the ﬁnger and be ﬁxed at the right diameter with Velcro.
By ﬁxing the diameter in this way, tube inﬂation would decrease the inner diameter
of the cuﬀ and exert a deﬁnite internal force on the ﬁnger, regardless of ﬁnger
diameter. The three independent air supplies can be seen in Figure 4.5 as the three
tubes extending to the right. By inﬂating the three expandable cuﬀs in sequence, a
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peristaltic eﬀect was induced in the ﬁnger to create the artiﬁcial pulse. The whole
cuﬀ assembly can be seen as Figure 4.7, while all pneumatic components used can
be seen in Appendix C.
Figure 4.7: APG Pressure Cuﬀ
4.4 Software Development and Signal Processing
The software development entailed the development of a graphical user interface
(GUI) to enable any user to easily operate the data acquisition system. The signal
processing of the collected data was not included in the GUI, although this would
be feasible for future versions.
4.4.1 Graphical User Interface
The Matlab-based GUI was primarily developed to simplify the data acquisition
procedure. It was thus mainly used during the in vitro calibration and in vivo
validation stages of the project. These stages will be discussed in Sections 4.5.3
and 4.6.2. A screen shot of the GUI can be seen in Figure 4.8.
The GUI only incorporated the most basic input parameters needed to collect
and store the PPG and reference saturation data in MS Excel format. Other,
more advanced, parameters were hard coded into the GUI m-ﬁle. These included
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Figure 4.8: GUI
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pressure cuﬀ inﬂation sequence and timing and data collection time. In future
versions of the GUI, inclusion of these parameters would be an option under an
advanced parameter tab.
4.4.2 Signal Processing
The processing of the red and infrared PPGs was done using Matlab. The PPGs
were processed to extract the normalized red-over-infrared ratio R. This ratio was
then correlated with a speciﬁc blood oxygen saturation. The basic R extraction
process can be seen as Figure 4.9. As the processing methods for both red and
infrared PPGs were the same, the method will only be discussed in general.
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Plot IR Data on
Figure 1
Filter IR Data
using FFT Filter
Load R Data
Plot R Data on
Figure 1
Filter R Data using
FFT Filter
Plot Filtered IR
Data on Figure 1
Determining
Sensitivity for
Peak Detection
Identifying Peaks
and Troughs
Plot Filtered R 
Data on Figure 1
Determining
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Peak Detection
Identifying Peaks
and Troughs
Synchronizing
Peak and Trough
Values
Synchronizing
Peak and Trough
Values
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and IR Peaks and
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Statistical Analysis
Plotting R Values
on Figure 2
Determining
Average R value
Figure 4.9: Signal Processing Overview
In Figure 4.9, the ﬁrst steps were to load and plot PPG data. These data
were stored in MS Excel format during the data acquisition stage, as explained in
Section 4.4.1. Typical PPG data can be seen in Figure 4.10.
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The frequency content of every PPG was initially examined using a Fast Fourier
Transform, as seen in Figure 4.10(b). The y-axis values of the PPG in Figure 4.10(a)
are arbitrary values allocated during the A/D conversion of the detected light in-
tensities. The initial examinations revealed that random noise was almost always
present in the PPGs. This noise would cause accuracy problems, as the actual peak
and trough values of the PPG were used to calculate R. The major frequencies of
this noise was always above 5 Hz and since the major pulse frequency content was
usually below this frequency, a low pass digital ﬁlter was implemented at 5 Hz.
In selecting this ﬁlter frequency, care was taken to ensure that only low energy
harmonic pulse frequencies were ﬁltered. It was assumed that since both red and
infrared PPGs had the same major frequencies, ﬁltering out pulse harmonics would
not have a major eﬀect on the calculation of R. After ﬁltering the signal, the ﬁltered
signal was plotted with the unﬁltered signal to allow visual inspection.
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Figure 4.10: Typical PPG (a) and FFT (b)
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The next step in processing the ﬁltered PPG was to identify peaks and troughs.
This was done using algorithms provided by Billauer (2007). This algorithm op-
erates on the basis of detecting peaks and troughs in a signal and verifying their
authenticity by checking if data points can be found on either side that are lower
by a speciﬁed margin in the case of peaks and higher in the case to troughs. This
margin corresponds to the sensitivity parameter shown in Figure 4.9. Detection
sensitivity was calculated by subtracting the minimum signal value from the max-
imum and dividing the result with a user speciﬁed parameter. This parameter was
usually in the range two to ﬁve and was selected based on an initial visual inspec-
tion of peak detection eﬃciency. This parameter was included to provide a simple
method of adapting the peak and trough detection for poor PPG quality scenarios.
By calculating sensitivity in this manner, it was ensured that peaks and troughs
would not be missed in low perfusion scenarios.
After identifying all the peaks and troughs in the PPG, individual peak and
trough values had to be synchronized. This was done to ensure that instantaneous
values were as accurate as possible. Peak and trough values were identiﬁed where
the time elapsed in between the peak and trough was less than half the average
period of the PPG. In the event of a peak having both the trough before and after
falling into this window, the closest trough was selected. This combination of a
peak and its closest trough will be referred to as a peak-trough throughout this
thesis.
Having identiﬁed the peak and trough pairs for the simultaneously recorded red
and infrared PPGs, the red and infrared pairs had to be synchronized. This was
achieved by grouping red and infrared pairs together where the time associated
with each infrared peak fell into a 0,3 sec window around the red peak.
The normalized red/infrared ratio R was calculated for each peak-trough pair by
ﬁrst calculating the diﬀerence between individual peak and trough values for the red
and infrared PPGs. This diﬀerence was then normalized with the average between
the peak and trough values. After this, the normalized diﬀerence for each red
peak-trough pair were divided by the normalized diﬀerence for the corresponding
infrared peak-trough pair to obtain R.
These values for R were statistically analyzed before averaging using a box-
and-whisker analysis as outlined by Vining (1997). Using this method, mild and
extreme outliers were identiﬁed and discarded, provided that the unquestionable R
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values were enough to deliver a meaningful average value for R. In the event of a
lack of unquestionable values, the sensitivity parameter and ﬁlter cutoﬀ frequency
were revised. If this did not increase the number of unquestionable values, the
averaged value for R was marked as possibly corrupt. Results for an exaggerated
and real situation box-and-whisker analysis can be seen as Figures 4.11 and 4.12.
In Figures 4.11 and 4.12 a range of R values were analyzed for mild and extreme
outliers and marked accordingly. The exaggerated results of Figure 4.11 were ob-
tained from initial experiments where the stability of R was low, while Figure 4.12
shows more stable R values from later experiments.
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Figure 4.11: Exaggerated Statistical Analysis of R
After the averaged value for R was calculated, the blood oxygen saturation that
corresponded with this value of R were found by utilizing a lookup table formulated
during the in vitro calibration phase. This stage of the project will be discussed
in Section 4.5. An alternative to this approach was to utilize a calibration curve
calculated using the system simulation as discussed in Section 4.2.2.A for SaO2 and
Section 4.2.2.C for SvO2. Results for both these approaches will be discussed in
Chapter 5.
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Figure 4.12: Real Statistical Analysis of R
4.5 System Calibration
All pulse oximeters rely on a calibration procedure to obtain R values for speciﬁc
SpO2 values. This calibration procedure is a critical stage in the development of a
pulse oximeter and eventually plays a major role in the accuracy of the system.
Two calibration approaches are possible, namely theoretical and empirical. The
theoretical approach based on Beer-Lambert's law has been shown to be inaccu-
rate, although recent revisions of Beer-Lambert's law have shown improved accu-
racy (Schmitt, 1991). Empirical calibration is currently the method of choice for
pulse oximeter manufacturers, due to its accuracy (Webster, 1997). The empirical
calibration route was also followed in this study, although theoretical results, as
obtained from the model discussed in Section 4.2.2.A, will be compared with this
approach in Section 5.4.
Empirical calibration procedures typically entails measuring a reference quan-
tity, with optical properties resembling human tissue with a known SaO2, to obtain
R values correlating to a speciﬁc SpO2. As stated earlier, the end result of this
calibration procedure is a calibration curve which correlates R to SpO2.
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4.5.1 Available Empirical Calibration Methods
The empirical calibration approach can be divided into two diﬀerent categories,
namely in vivo and in vitro procedures.
In vivo calibration entails directly comparing R values obtained by measur-
ing human subjects to SaO2 values obtained from blood samples withdrawn from
the subjects. Subjects are systematically desaturated by inhaling mixtures of air
that contains decreasing concentrations of oxygen. SaO2 values are obtained by
analyzing blood samples from the subjects at each step using a multi-wavelength
co-oximeter. Measured R values are plotted against the reference SaO2 values to
obtain the calibration curve. The in vivo procedure is currently used by the major-
ity of manufacturers (Stabile and Reynolds, 2002), due to its inherent accuracy as a
result of the real physiological parameters present during the calibration procedure.
One disadvantage of this procedure lies in the fact that due to the possibility of
brain damage at saturations below 70%, in vivo calibration curves are only based
on real values in the region of 70-100% saturation (Stabile and Reynolds, 2002;
Hornberger et al., 2002). Below 70% saturation, the calibration curve is based
on the extrapolation of the real data, resulting in notoriously inaccurate readings
below 70%. Additionally, eﬀective in vivo calibration is a costly and complex proce-
dure and is only conducted by the manufacturers themselves and a few specialized
laboratories (Hornberger et al., 2002).
In vitro calibration entails comparing R values obtained by measuring the trans-
mittance or reﬂectance of light of a tissue phantom or simulator that is able to
accurately mimic the optical properties of tissue perfused with blood at a spe-
ciﬁc saturation. The type of tissue phantom distinguishes the diﬀerent types of
in vitro procedures. Tissue phantoms vary in composition of the optical absorb-
ing substance, some utilizing blood, others blood simulating substances and some
opto-electronic or purely electronic systems (Stabile and Reynolds, 2002).
Blood phantoms, as used by Edrich et al. (1998), Edrich et al. (2000) and
Volgyesi et al. (1990), are phantoms where human blood is used as primary absorber
in a cuvette which mimics the absorption and scattering properties of bloodless
tissue, bone and skin. Blood is pulsed through the cuvette or rotated in a mechanical
system to mimic the pulsatile behaviour of blood in the arterioles and capillaries
(Stabile and Reynolds, 2002). The saturation of this blood is controlled using
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an oxygenator and measured using a reference co-oximetry system. R values are
measured on the phantom whilst the blood is systematically desaturated. The
main advantages of using this approach includes the use of blood as an absorber
and the ability to desaturate the blood to very low values. Disadvantages include
the diﬃculty of obtaining stable saturation values, the complexity of obtaining a
cuvette which accurately mimics tissue absorbing and scattering properties (Stabile
and Reynolds, 2002) and the detrimental eﬀects of pulse shape and blood ﬂow
velocity in cuvette systems (Edrich et al., 1998).
Tissue phantoms that employ techniques that simulate the absorption and scat-
tering properties of human blood, have been used by Leuthner (1994), Mundley
et al. (1989), Aoyagi (1994) and Zhou et al. (1993). In the ﬁrst three of these
systems, the light absorption properties of blood was simulated by either solutions
infused with diﬀering amounts of dye or tinted resins. These blood simulating ab-
sorbers were mechanically manipulated to induce pulsatile absorption behaviour.
The system used by Zhou et al. (1993), utilized a liquid crystal retarder (LCR)
to simulate the pulsatile absorption properties of blood. By adjusting the supply
voltage to the LCR, the intensity of the light transmitted through the LCR could
be modulated, while polarizers provided the static absorption that originates from
bloodless tissue, skin and bone. The advantage of using these systems was the
degree of standardization that could possibly be achieved, as well as eliminating
the problems associated with working with human blood. Disadvantages included
the complexity of accurately preparing the absorbers and scatterers to simulate the
optical properties of human blood and bloodless tissue, skin and bone, as well as
ignoring many of the complex liquid crystal properties in the case of Zhou et al.
(1993) (Stabile and Reynolds, 2002).
An opto-electronic calibrator, as designed by Hornberger et al. (2002), oper-
ated under the principle of isolating the sensors LEDs from the photodetector and
simulating light-tissue interaction based on data stored on a PC. In the system
designed by Hornberger et al. (2002), a spectrometer and photodetector unit were
used to analyze the sensor LED's optical properties. These properties were used as
input to a computer algorithm with access to a large database of patient transmis-
sion spectra. Using user-speciﬁed patient spectra, with their corresponding arterial
saturations, the transmission properties of light emitted by the sensor LEDs were
calculated and simulated using LEDs on the calibrator. Light emitted by the cali-
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brator LEDs were detected by the sensor photodetector. Main advantages of using
this system, includes the re-usability of recorded patient data and the high degree
of standardization that can be achieved. The main disadvantages of this system
are the limitations on sensor models that can be tested, as a result of the calibrator
LED wavelengths, as well as the fact that infrared emission by the red LED was
ignored (Hornberger et al., 2002).
Purely electronic simulators, such as the SmartSat Pulse Oximetry Analyzer
manufactured by the Clinical Dynamics Corporation (Clinical Dynamics Corpora-
tion, 1996), employ a probe that directly plugs into the sensor port of the pulse
oximeter. The simulator processes the LED driving currents and sources a simu-
lated photodetector current to the pulse oximeter. This photodetector current is
modulated according to LED driving current and a database containing manufac-
turer supplied calibration information. Advantages of using this system includes
the high degree of standardization that can be achieved and the capability of ef-
fectively simulating a variety of physiological scenarios. The main disadvantage is
the dependency of the simulator on manufacturer supplied calibration information
(Stabile and Reynolds, 2002).
A calibration technique using a blood phantom as described by Edrich et al.
(2000), was used in this study. The selection of this technique was based upon the
need to calibrate the APO at high and very low saturations and the special wave-
lengths of light used at low saturations. The low saturation calibration requirement
eliminated the possibility of using an in vivo calibration technique. Additionally, the
complexity and repeatability issues of preparing solutions that accurately simulate
the light absorbing properties of human blood at various saturations, eliminated the
blood simulators as a possibility. The opto-electronic and electric calibrators were
not an option, based upon their dependency on data collected for speciﬁc wave-
lengths used by speciﬁc sensors. As mentioned earlier, the selected blood phantom
method also has its drawbacks, but care was taken to minimize these factors during
calibration.
4.5.2 Calibration Setup
The in vitro setup utilized to calibrate the sensor hardware was selected based
on the ability for low saturation calibration and the inherent accuracy that could
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be obtained through the use of human blood. This calibration setup was derived
from studies done by Edrich et al. (1998) and Edrich et al. (2000) and is shown in
Figure 4.13.
Figure 4.13: In Vitro Calibration Layout
The calibration setup consisted of two identical calibration sub-circuits, namely
the arterial and venous circuits. These circuits could be connected by means of a
three-way valve assembly. The arterial circuit was used to calibrate the sensors for
conventional operation, while the venous circuit was used in conjunction with the
arterial circuit to verify the hypothesis that the overall absorption by two volumes
of blood with diﬀering oxygen saturations would be a linear combination of the
individual saturation values. The circuit was an open system designed to circulate
human blood through an optical cuvette at a user-speciﬁed oxygen saturation.
A constant ﬂow peristaltic pump was used to circulate the blood after removing
one of the two impeller arms to obtain pulsatile ﬂow. Non-return valves from Festo
had to be included to prevent blood ﬂowing back to the pump during the non-
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contact periods caused by removing the impeller arm. Pulse rate was controlled by
adjusting the rotational speed of the pump.
A D901 Lilliput 1 oxygenator from Dideco was used to oxygenate or deoxygenate
the circulating blood. Oxygenation or deoxygenation was achieved by either con-
necting a 100% oxygen supply or a 95% nitrogen and 5% carbon dioxide mixture
to the oxygenator. A lean mixture of carbon dioxide was used decrease the degree
of desaturation during a desaturation step. This increased the resolution of the
calibration curve by increasing the amount of saturation points measured during
the desaturation sequence. The laboratory setup, showing the Lilliput oxygenator
on the left and the peristaltic pump on the right, can be seen in Figure 4.14
Figure 4.14: In Vitro Calibration Setup
A tri-chamber stainless steel cuvette was used in this study, inspired by the
dual-chamber cuvette designed by Edrich et al. (2000). The tri-chamber cuvette
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was designed to provide for separate arterial and venous blood channels, as well as
a diﬀusor chamber. A cross-sectional view of the cuvette is shown in Figure 4.15.
Arterial Blood Inlet Port 
Venous Blood Inlet Port 
Arterial Blood Outlet Port 
Venous Blood Outlet Port Port for Photodiode
Pyrex
Pyrex Flexible Membrane 
Flexible Membrane 
Diffusor - 2% Fat Milk 
Port for LEDs 
Figure 4.15: Cuvette Cross-section
Homogenized 2% low fat milk was used as a diﬀusor to simulate the scattering
properties of bloodless tissue, skin and bone (Edrich et al., 2000). The chambers
were seperated by ﬂexible membranes that would outwardly deform if pressure was
applied to the chambers. This simulated the physiological conditions studied by
Aoyagi (1994), where light absorption changed inversely with respect to absorber
depth. AC behaviour in the PPG was mainly due to changes in blood channel depth
during pressure ﬂuctuations caused by the pump. Milk pressure was not regulated
in this study. The blood ﬂow channel and diﬀusor chamber dimensions was selected
at 0,3 and 4,0 mm to simulate a blood volume percentage of approximately 10%
in human tissue. The cuvette was designed using stainless steel to prevent external
light contamination of the PPGs. Pyrex glass was selected as the windows for the
LEDs and photodiode, based on the assumption that any optical interference by
the glass would be included in the DC component of the PPG.
The assembled cuvette can be seen as Figures 4.16 and 4.17, while detailed
drawings can be found in Appendix C. Barbed nipple ﬁttings from Festo, with cat-
alogue numbers speciﬁed in Appendix C, were used as interface with the circulatory
system.
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Sensor Placement 
Arterial Blood 
Outlet Port 
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Scattering Medium Port
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Venous Blood Inlet Port
Figure 4.16: 3-D Cuvette Model
4.5.3 Calibration Procedure
The overall goal of the calibration procedure was to obtain a calibration curve,
where the APO's output ratio R could be correlated with blood oxygen satura-
tion values. This process entailed measuring R whilst desaturating fully saturated
human blood to a value of SO2 ≤ 10%.
Expired whole human blood from the blood repository at Tygerberg Academical
Hospital was used as principal absorber during the calibration test. Care was taken
to ensure that blood more than three days past the expiry date was not used. Older
blood displays advanced levels of haemolysis, resulting in diﬀerent optical properties
than that of normal human blood. Three days were assumed a safe cutoﬀ limit,
as blood that is close, but still within its expiry date, is still suitable for human
use and does not deteriorate rapidly under refrigerated conditions. All blood was
tested before calibration for elevated lactate and low hematocrit levels, both being
indicators of haemolysis. A hematocrit of 26% was considered to be the lower limit
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Figure 4.17: Assembled Cuvette
for inclusion.
The calibration procedure was divided into two phases, namely conventional
arterial calibration and arterio-venous validation. During the conventional arterial
calibration only the arterial circuit in the calibration setup was used. Both the ar-
terial and venous circuits were used during the arterio-venous validation stage. The
calibration procedures for the 660/910 nm and 740/880 nm sensors were conducted
as two separate runs, although the procedures were identical for both sensors.
For the arterial calibration, the entire circuit was ﬁrst primed using a 0.9% saline
solution. Homogenised 2% low fat milk was injected into the diﬀusor chamber. All
excess saline in the oxygenator's reservoirs was drained via a three-way valve at the
lower part of the circuit. Approximately 500 ml of blood was directly injected into
the oxygenator's venous reservoir via an input port on the reservoir. The peristaltic
pump was started and the drainage valve was used again to drain excess saline in
the piping of the system. This excess saline drainage was done to keep hematocrit
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levels as close as possible to normal.
A 100% supply of O2 was connected to the gas port of the oxygenator and
enough time was allowed for the whole blood sample to be fully oxygenated whilst
the pump circulated the blood. A blood sample was taken via a sample port
included in the circuit directly after the oxygenator. This sample was analyzed
for ScO2 using a Bayer Rapidlab 865 blood gas analyzer. This analyzer was used
as the golden standard reference system throughout the in vitro calibration phase.
The sensor being calibrated was activated and PPG data recorded for a period of
48 seconds using the GUI as discussed in Section 4.4.1. These data were stored
in conjunction with the reference ScO2 value as determined using the blood gas
analyzer.
The O2 supply was now disconnected and replaced with the 95% N2/CO2 gas
supply to deoxygenate the blood. A short period of time was allowed for a volume
of blood to be partially deoxygenated as the blood was circulated by the pump.
The deoxygenation process occurs as a result of the low O2 concentration in the
capillary gas exchange surfaces of the oxygenator. O2 diﬀusing from the blood to
the gas exchange system is removed from the system by the ﬂow of excess N2/CO2
that vents to the atmosphere. The N2/CO2 supply was stopped after a short period
and enough time was allowed for the saturation to stabilize throughout the system
at a lower value. A reference blood gas sample was taken and analyzed for ScO2.
PPG data was again recorded and stored in conjunction with the reference ScO2
value.
This deoxygenation process was conducted repeatedly to obtain data at stepwise
decreasing saturation values, down to a saturation value ≤ 10%. This completed
the data recording stage of the arterial calibration.
The stored PPG data were analyzed and averaged R values calculated using
the software approach as outlined in Section 4.4.2. Using the calculated R and
corresponding ScO2 values, the arterial calibration curves for the 660/910 nm and
740/880 nm sensors were constructed. These curves will be displayed and discussed
in Section 5.2.
As mentioned earlier, the arterio-venous validation phase used both the arterial
and venous circuits. Both circuits were primed in a similar manner to the arte-
rial calibration phase and milk injected into the diﬀusor chamber. Approximately
1000 ml of whole blood was injected into the oxygenator's venous reservoir and
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excess saline drained.
The blood was fully oxygenated using the O2 supply, whilst circulating through
both the arterial and venous circuits. Reference blood samples were taken from
both the arterial and venous circuits and analyzed, whilst PPG data for the sensor
were collected. This PPG data was stored in conjunction with the reference ScO2
values for both circuits.
The arterial circuit was then isolated from the venous circuit using a three-way
valve system. Only the venous blood now circulated through the oxygenator, whilst
the arterial blood bypassed the oxygenator and was fed back directly to the pump
and cuvette. The N2/CO2 supply was now connected to the gas port, replacing the
O2 supply. A short period of time was allowed for a volume of the venous blood to
be partially deoxygenated. The N2/CO2 supply was stopped and time allowed for
the saturation in the venous circuit to stabilize. This dual process was conducted
to provide two separate circuits, containing blood at diﬀerent saturations, ﬂowing
through the cuvette. A dual reference sample was withdrawn from the arterial and
venous circuits, analyzed for ScaO2 and ScvO2 and stored with PPG data collected
during the analysis.
The venous desaturation and PPG data collection was repeated until ScvO2
reached a value of approximately 60%. After completing the data collection stage,
the combined averaged R values for both circuits were calculated using the approach
outlined in Section 4.4.2. The results will be shown and discussed in Section 5.2.
4.6 System Validation
The system validation phase of the prototype development entailed collecting and
analyzing PPG data from human volunteers and using these data in correlation
with the calibration curves presented in Section 5.2 to calculate either SpaO2 or
SpvO2. These calculated values were compared with reference ScaO2 or ScvO2 values
obtained using a Bayer Rapidlab 865 blood gas analyzer to analyze blood samples
withdrawn from the volunteers.
Four objectives were identiﬁed for the system validation. These were:
1. To verify the operation of the APG.
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2. To determine the accuracy of the calibration curves presented in Section 5.2
at high saturation values. This objective involved only the 660/910 nm sensor
in conventional pulse oximeter mode, as this sensor was well-suited to high
saturation values and naturally detectable PPG data was available.
3. To determine the accuracy and validity of the hypothesis that that the overall
absorption by two volumes of blood with diﬀering oxygen saturations would
be a linear combination of the individual saturation values. Only the 660/910
nm sensor was tested in conjunction with the APG for this objective, due to
time constraints imposed by the testing procedure. This will be discussed in
more detail in Section 4.6.2.
4. To determine the accuracy of above-mentioned calibration curves for both
the 660/910 nm and 740/880 nm sensors at low saturations. The APG was
used to generate artiﬁcial PPG data for this objective.
4.6.1 Test Population
Ethical approval for conducting the in vivo tests was obtained from the Comittee of
Human Research at the University of Stellenbosch. Twelve Volunteers, complying
with inclusion criteria, were recruited from the University of Stellenbosch campus.
The inclusion criteria were:
1. Volunteer weight ≥ 50 kg
2. Volunteer age ≥ 18 years
3. Written informed consent had to be given
4. Volunteer blood parameters had to be normal
All in vivo tests were conducted at Tygerberg Academical Hospital on six dif-
ferent days. Two volunteers were tested during each day, with each test lasting
approximately 30 minutes.
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4.6.2 Procedure
The room in which the clinical testing was conducted, was prepared beforehand by
the clinical assistant. The system was set up in the prepared room and pretesting
procedures completed to ensure correct operation of the system.
Each test subject was ﬁrstly informed on all the risks associated with the test
procedure and was required to sign a written informed consent form to participate
in the testing. The subject was then asked to sit in a chair next to the test bench
to support the subject's left arm and to keep movement to a minimum during the
testing procedure.
A pressure cuﬀ from a conventional sphygmomanometer was wrapped around
the subject's lower left arm, to be inﬂated during a later stage of the validation
procedure to simulate the occluded nature of tissues aﬀected by peripheral vascular
aictions. Occlusion had to be simulated to validate the APO's performance, due
to the lack of patients suﬀering from diseases such as meningococcemia. The APG's
pressure cuﬀ was positioned around the subject's left hand index ﬁnger. After this,
the 660/910 nm sensor was positioned on the tip of the subject's left hand index
ﬁnger. This setup can be seen in Figure 4.18.
A capillary blood sample was withdrawn from the subject's right hand by means
of a normal blood withdrawal procedure conducted by the clinical assistant. The
ScaO2 of this blood sample was measured using a Bayer Rapidlab 865 blood gas
analyzer. This saturation value served as the golden standard for comparison with
SpaO2 values calculated by the APO system . Three SpaO2 values were sequentially
measured, using the system with the 660/910 nm sensor in a similar manner to
conventional systems, with the wrist cuﬀ and APG deﬂated or inactive. All PPG
and saturation data were stored in MS Excel. This concluded the high saturation
validation procedure. Results for the high saturation validation will be discussed
in Section 5.3.2.
For the APG operation and arterio-venous hypothesis validation objectives, the
wrist cuﬀ was inﬂated to a pressure of 160 mmHg. This pressure was suﬃcient to
cut oﬀ all normal blood circulation to the subject's hand to simulate the occluded
nature of aﬀected tissue. Occluded PPG data were collected and stored for the
validation of the APG's performance. A venous blood sample was immediately
withdrawn from a vein on top of the subject's left hand and analyzed using the
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Figure 4.18: In Vivo Validation Setup
blood gas analyzer to obtain a ScvO2 value. The APG was activated directly
after withdrawing the venous sample. The artiﬁcial PPG that was induced in
the ﬁnger was measured using the 660/910 nm sensor, analyzed for SpvO2 and
stored in conjunction with the reference ScvO2 value. In testing the validity of the
arterio-venous hypothesis, stated as objective three in Section 4.6, it was assumed
that SaO2 would remain stable for long enough after occlusion to assume that
the ScaO2 measured for the high saturation validation could be used as input to
calculate SpvO2. Due to the time needed to collect PPG data for the 660/910 nm
sensor, SaO2 would decrease to a unknown value if PPG data had to be collected
for the 740/880 nm sensor as well. Thus only the 660/910 nm sensor was tested
in validating the arterio-venous hypothesis. Results for the APG operation and
arterio-venous hypothesis validation will be discussed in Sections 5.3.1 and 5.3.4,
respectively.
The wrist cuﬀ was kept inﬂated for a short period of time, typically 5 minutes, to
allow overall saturation values in the tip of the subject's left index ﬁnger to decrease
to a suitably low value. This was done as to validate the low saturation performance
of the APO, as stated in Section 4.6. Care was taken to ensure that the time elapsed
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from wrist cuﬀ inﬂation to wrist cuﬀ deﬂation did not exceed 10 minutes to ensure
that no tissue damage occurred due to O2 deprivation. The subject was in control
of the pressure release valve of the lower arm cuﬀ at all times to enable him/her to
release the pressure if undue discomfort was experienced in the hand. A capillary
blood sample was withdrawn from one of the subject's left hand ﬁngers by the
clinical assistant. Due to the occlusion of the hand, it was not always possible to
obtain a full blood sample from one ﬁnger alone. In the event of this happening,
a second ﬁnger was pricked and palpated to obtain a full sample. Diﬀerences in
the capillary saturation values between ﬁngers were assumed to be negligible. The
blood sample was analyzed to obtain a ScO2 value using the reference blood gas
analyzer. The APG was activated directly after withdrawing the capillary sample.
The artiﬁcial PPG that was induced in the ﬁnger was measured by ﬁrst using the
660/910 nm sensor and then the low saturation 740/880 nm sensors. All PPG
data were processed to obtain SpO2 values and stored in conjunction with the
measured ScO2 values. Results for the low saturation validation will be discussed
in Section 5.3.3.
After the procedure was completed, the APG system was deactivated by means
of the GUI on the PC and the APG deﬂated. The lower arm cuﬀ was deﬂated and
removed, restoring normal blood circulation in the subject's hand. After this, the
sensor and APG was removed from the subject's ﬁnger, signaling the end of the
validation procedure.
Chapter 5
Results
An overview of the system development as described in Chapter 4 can be seen
in Figure 5.1. The main aim was to accurately measure SO2. A system was
designed to measure SO2 in low saturation and perfusion scenarios. The system
was calibrated using an in vitro calibration approach and the calibration results
were veriﬁed with a photon diﬀusion theory system simulation. Using the empirical
and simulated calibration results, the system was used to calculate either SpaO2 or
SpvO2. The calculated results were validated with reference SO2 values measured
by means of a co-oximetry system.
Figure 5.1: System Development Overview
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5.1 System Simulation
As mentioned in Section 4.2, a system simulation was conducted to verify and pro-
vide information on calibration curve behaviour subjected to various physiological
scenarios which could not necessarily be investigated using an in vitro or in vivo ex-
perimental setup. In this study, the propagation properties of light through human
tissue was modeled using photon diﬀusion theory.
Using the approach followed by Schmitt (1991), a mathematical relationship
between R and SaO2 for conventional pulse oximetry was derived as Equation 4.5.
This relationship was modiﬁed to include the eﬀects of venous pulsatile behaviour,
as seen in Equation 4.25. These relationships could then be used to calculate
the theoretical calibration curves for speciﬁed sensors utilizing LEDs at speciﬁc
wavelengths. Calibration curves for the 660/910 nm and 740/880 nm sensors are
depicted in Figures 5.2 and 5.3. The optical constants that was used as input to
these models can be found in Table 4.3. The theoretical calibration curves could be
used to calculate SpO2 from the value of R calculated from a normal physiological
PPG. A more detailed discussion of this application will be provided in Section 5.3.
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Figure 5.2: Simulated 660/910 nm Calibration Curve (H=45%; Va=Vv=5%; d=10 mm;
F=0.013; Arterio-Venous ∆SO2=10%)
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Figure 5.3: Simulated 740/880 nm Calibration Curve (H=45%; Va=Vv=5%; d=10 mm;
F=0.013; Arterio-Venous ∆SO2=10%)
As can be seen from Figures 5.2 and 5.3, the 660/910 nm sensor is more sensitive
to changes in SaO2 than the 740/880 nm sensor. This behaviour is due to the
selection of wavelengths to maximise the quantities (σ0%ab,ir−σ100%ab,ir ) and (σ100%ab,r −σ0%ab,r)
in Equation 4.5, as noted by Schmitt (1991). This is the approach normally followed
by pulse oximeter manufacturers to optimise sensor performance.
The system simulation was valuable in the sense that it could provide infor-
mation on the behaviour of the calibration curves when subjected to changes in
physiological variables, such as hematocrit, blood volume, ﬁnger thickness and
arterio-venous saturation diﬀerence. Changes in the order of natural variation,
have been studied and recorded by Schmitt (1991). Examples of curve behaviour
subjected to changes in blood volume and hematocrit are shown in Figures 5.4 and
5.5.
As can be seen from Figures 5.4 and 5.5, variations in physiological parameters
only have a notable eﬀect on the calibration curve when saturation values decrease
to less than 70-80%. It is well known in the medical community that conventional
pulse oximeter functionality is questionable in the low saturation range, a fact
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Figure 5.4: Simulated Blood Volume Variation in 660/910 nm Calibration Curve
(H=45%; d=10 mm; F=0.013; Arterio-Venous ∆SO2=10%)
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Figure 5.5: Simulated Hematocrit Variation in 660/910 nm Calibration Curve
(d=10 mm; F=0.013; Va=Vv=1%; Arterio-Venous ∆SO2=10%)
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that has been experimentally veriﬁed in studies done by Severinghaus and Naifeh
(1987) and Severinghaus et al. (1989). This inaccuracy is probably due to the fact
that most manufacturers utilize a high saturation in vivo calibration procedure
and extrapolates this calibration data into the lower saturation range (Stabile and
Reynolds, 2002), neglecting the eﬀects of physiological variations as shown above.
As mentioned earlier, a mathematical relationship between R, SaO2 and SvO2
was developed to simulate calibration curves for arterial and venous pulsatile or
arterio-venous behaviour. As can be seen from Equation 4.25, R is dependent on
both SaO2 and SvO2, resulting in 10 000 (100x100) possible calibration curves for
diﬀerent combinations of SaO2 and SvO2 if the curves are based on a 1% resolution.
If it is assumed that SaO2 is known, a calibration curve relating R and SvO2 could
be calculated. These curves for the 660/910 nm sensor are plotted in Figure 5.6 for
diﬀerent values of SaO2.
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Figure 5.6: Simulated SaO2 Variation in 660/910 nm Calibration Curve (H=45%;
d=10 mm; F=0.013; Va=Vv=1%
The slope of the R/SvO2 calibration curve is dependent on the arterial-to-venous
compliance ratio, as discussed in Section 4.2.2.C, while the overall y-coordinate
placement of the curve is dependent on SaO2. An arterial-to-venous ratio of 1:2
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would for example, deliver a calibration curve with a steeper slope than that of a
arterial-to-venous ratio of 2:1. The dependency of y-coordinate placement on SaO2
can be seen in Figure 5.6.
5.2 System Calibration
A system calibration was conducted to obtain wavelength speciﬁc calibration curves.
Based on an existing calibration method analysis done in Section 4.5.1, an in vitro
calibration procedure, using a blood phantom, was used. Three sets of calibration
runs were conducted during this phase of the system development. These were the
calibration of the 660/910 nm sensor, the calibration of the 740/880 nm sensor and
the in vitro arterio-venous validation.
During the calibration procedures for both the 660/910 nm and 740/880 nm
sensors, only the the arterial sub circuit of the calibration setup, as outlined in
Section 4.5.2, was used. Blood was ﬁrstly fully oxygenated and then deoxygenated
in a stepwise manner, whilst collecting, storing and analyzing PPG data. Cali-
bration curves for the 660/910 nm and 740/880 nm sensors, calculated using the
approach outlined in Section 4.5.3, are plotted in Figures 5.7 and 5.8. The data
collected for the curves were ﬁtted with quadratic polynomials based on the curved
behaviour of the simulation results presented in Figures 5.4 and 5.5. Commercial
calibration curves, as presented by Nellcor Technical Staﬀ (2004), Schmitt (1991)
and Zonios et al. (2004) also exhibit this quadratic behaviour. In Figures 5.7 and
5.8 the diﬀerent symbols represents diﬀerent data sets and the lines the quadratic
ﬁts to these data sets.
The three diﬀerent datasets presented for the 660/910 nm sensor calibration
curves in Figure 5.7, resulted from an iterative procedure to perfect the calibra-
tion procedure. During the ﬁrst calibration procedure, the excess saline was not
drained from the venous reservoir of the Lilliput oxygenator, resulting in a very low
hematocrit (H=13%) calibration curve. Only one unit of expired whole blood was
available for this calibration run. For the second calibration run, the excess saline
was drained from the oxygenator's venous reservoir, as explained in Section 4.5.3,
but not from the circuit piping. This resulted in a higher, but still lower than nor-
mal, hematocrit (H=24%) calibration curve when the saline mixed with the single
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Figure 5.7: In vitro Empirical 660/910 nm Calibration Curve
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Figure 5.8: In vitro Empirical 740/880 nm Calibration Curve (H=38%)
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Table 5.1: In Vitro Arterio-Venous Validation Results
Sensor Trial Signal R SpvO2 Reference
# Qualitya Stabilitya Simulationb Curve ScvO2
660/910 nm 1 + 0 82 89 83
660/910 nm 2 - - 46 57 75
660/910 nm 3 + - 29 41 71
660/910 nm 4 + 0 50 63 63
740/880 nm 1 + 0 1 1 83
740/880 nm 2 - - 1 72 75
740/880 nm 3 + + 22 100 71
740/880 nm 4 + + 1 48 63
a(+) Good; (0) Average; (-) Bad
bH=45%; d=10 mm; F=0.013; Va=Vv=5%
available whole blood unit for this run. During the third calibration procedure,
these issues were eliminated by ﬁrst draining the excess saline from both the oxy-
genator's venous reservoir and the circuit piping before injecting the blood and by
using two units of expired whole blood. This iterative procedure had the bonus
of displaying in what manner hematocrit changes can aﬀect empirical calibration
curves.
As can be seen from Figures 5.7 and 5.8, the 660/910 nm sensor's calibration
curve has a steeper slope than that of the 740/880 nm sensor, verifying the 660/910
nm sensor's superior sensitivity to changes in SaO2, as discussed in Section 5.1
Both the arterial and venous circuits in the calibration setup were used during
the in vitro arterio-venous validation stage. The validation stage, as explained in
Section 4.5.3, entailed calculating SpvO2 from an R value calculated by measuring
arterial and venous pulsations. This calculation of SpvO2 was dependent on the
prerequisite that the value of SaO2 was known. Two blood samples were withdrawn
from the setup for each desaturation step and analyzed to obtain reference blood
gas values for ScaO2 and ScvO2. Calculated SpvO2 and reference ScvO2 values can be
seen in Table 5.1. PPG quality (shape and amplitude repeatability) and R stability
(repeatability of R values calculated for diﬀerent PPG peaks) is also indicated in
Table 5.1.
As can be seen from Table 5.1, the calculated SpvO2 values were generally
not in agreement with the reference ScvO2 values. Results were random and did
CHAPTER 5. RESULTS 80
not present any repeatable behaviour. This is probably due to the complexity to
set up the calibration experiment to accurately simulate physiological arterial-to-
venous compliance ratios. Additionally, pressure pulse propagation discrepancies in
the arterial and venous circuits would also deliver inaccurate results. The in vitro
validation phase was not continued after the initial tests, as the amount of variables
that could lead to inaccurate results were too many. The complete redesign of the
calibration setup that would be needed to account for all these variables, was not
considered a viable option. The validation of the arterio-venous hypothesis was
shifted to an in vivo approach, as discussed in Section 5.3.4.
5.3 System Validation
The system validation phase entailed the in vivo evaluation of the accuracy of the
simulated and empirical calibration curves presented in Sections 5.1 and 5.2 and
the repeatability of the measurements. As mentioned in Section 4.6, the system
validation phase had four objectives, namely, verifying the operation of the APG,
evaluating curve performance under conventional high saturation value conditions,
testing the validity of the arterio-venous hypothesis in conjunction with the AGP
and evaluating APO curve performance in low saturation value scenarios.
5.3.1 APG Veriﬁcation
The APG veriﬁcation objective was simply a visual comparison of occluded PPG
data before and after APG activation. PPG data for a subject before and after
APG activation is shown in Figure 5.9. As can be seen, the APG has a pronounced
eﬀect on pulse amplitude and shape, enabling the eﬀective extraction R which is a
factor of arterial and venous pulsatile behaviour. The y-axis in Figure 5.9 is rep-
resentative of arbitrary numbers allocated to the PPG during the A/D conversion
of the detected light intensities.
5.3.2 High Saturation Validation
Only the 660/910 nm sensor's calibration curves were evaluated during the high
saturation validation. This was due to the fact that the 660/910 nm sensor was
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Figure 5.9: PPG on Occluded Tissue Before and After APG Application
speciﬁcally designed to perform optimally under high saturation conditions. The
740/880 nm sensor is not optimally suited for high saturation scenarios and was
not used under these circumstances.
PPG and reference ScaO2 data were collected following the procedure described
in Section 4.6.2. The PPG data were analyzed to extract an averaged R value, using
the signal processing technique outlined in Section 4.4.2. These R values were used
as input to the theoretical and empirical calibration curves of the 660/910 nm
sensor to calculate SpaO2. The simulated curves used were calculated using the
same approach followed to obtain the calibration curve presented in Figure 5.2, but
with physiological parameters such as hematocrit and ﬁnger diameter individually
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adapted for each volunteer. Calculated SpaO2 values were analyzed for accuracy and
repeatability through comparison with the reference ScaO2 values. A comparative
representation of the ScaO2 and SpaO2 values measured for twelve volunteers are
depicted in Figures 5.10 and 5.11, whilst numerical ScaO2 and SpaO2 data can
be found in Appendix D. Figure 5.10 presents saturation data calculated using
the 660/910 nm sensor's empirical calibration curve, whilst Figure 5.11 presents
the calculated results using the simulated calibration curve. Diﬀerent symbols
represent data collected from diﬀerent volunteers.
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Figure 5.10: Empirical In Vivo High SO2 Results (In Vitro Curve)
As can be seen from Figures 5.10 and 5.11, both the empirical and simulated
calibration curves produce SpaO2 values that are situated beneath the diagonal line
representing the reference ScaO2 values. This indicates a low indication error in
both calibration curves, although it can be seen that the error for the empirical
calibration curve is smaller than that of the simulated curve. SpaO2 bias and pre-
cision, as calculated using the approach described by Bland and Altman (1986),
was -4.8±3.86% for the empirical calibration curve and -6.2±4.35% for the simu-
lated calibration curve. The bias error in the empirical calibration curve is most
likely due to the in vitro calibration approach that was followed, as opposed to
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Figure 5.11: Empirical In Vivo High SO2 Results (Simulated Curve)
the conventional in vivo calibration procedure as described in Section 4.5.1. The
in vitro method is subject to inaccuracies resulting from the simulation of tissue
properties by using a blood phantom, as opposed to the in vivo method, which is
not. The bias error resulting from the use of the simulated curve is most likely due
to small discrepancies between the physical process of light propagation through
human tissue and the modelling of light propagation as a diﬀusive process.
Intra volunteer results show small variations in SpaO2 values, indicating good
sensor repeatability. This good repeatability for the 660/910 nm sensor in high
saturation scenarios is in good agreement with studies done by Mannheimer et al.
(1997).
5.3.3 Low Saturation Validation
The low saturation validation was done to evaluate the accuracy and repeatability
of low saturation SpaO2 measurements calculated using the empirical and simu-
lated calibration curves, presented in Sections 5.1 and 5.2. The performance of
both the 660/910 nm and 740/880 nm sensors were evaluated, despite the fact
that the 660/910 nm sensor is not optimally suited for low saturation applications
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(Mannheimer et al., 1997).
In order to conduct the in vivo low saturation validation, low saturation condi-
tions had to be induced in the tissue under consideration. This was done following
a tissue occlusion procedure, as described in Section 4.6.2. Measurements were con-
ducted after a period of occlusion, to allow overall saturation values in the tissue
to decrease to a suitable level. It was assumed that SaO2 and SvO2 values would
be similar after a suﬃcient period of time, and that a general SgO2 could be used
for both. The APG was used to induce an artiﬁcial pulse in the occluded tissue.
Comparative representations of ScgO2 and SpgO2 values measured for twelve
volunteers with the 660/910 nm and 740/880 nm sensors, is depicted in Figures 5.12
to 5.15, whilst numerical ScgO2 and SpgO2 data can be found in Appendix D.
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Figure 5.12: Empirical 660/910 nm In Vivo Low SO2 Results (In Vitro Curve)
It is evident from Figures 5.12 and 5.13 that SpgO2 values calculated using
the empirical and simulated calibration curves are neither accurate, nor repeat-
able. This is in good agreement with low saturation studies done by Severing-
haus and Naifeh (1987), Severinghaus et al. (1989) and Mannheimer et al. (1997).
Mannheimer et al. (1997) postulates that these accuracy and repeatability issues
are as a result of a mismatch in mean photon path length changes at 660 nm and 910
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Figure 5.13: Empirical 660/910 nm In Vivo Low SO2 Results (Simulated Curve)
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Figure 5.14: Empirical 740/880 nm In Vivo Low SO2 Results (In Vitro Curve)
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Figure 5.15: Empirical 740/880 nm In Vivo Low SO2 Results (Simulated Curve)
nm. These photon path length changes are as a result of changes in physiological
parameters between calibration and validation.
Inaccuracies in calculated SpgO2 values could also result from inaccurate calibra-
tion curves at low saturations. Due to the low repeatability of the SpgO2 values, it is
diﬃcult to formulate a conclusion on the curve accuracy, but if bias errors are con-
sidered, the empirical calibration curve presented in Figure 5.14 seems to be more
accurate than the simulated calibration curve presented in Figure 5.15. The em-
pirical and simulated bias and precision values were -5±24.75% and -14.5±23.07%,
respectively.
Figures 5.14 and 5.15 show that SpgO2 values calculated using the 740/880 nm
sensor show similar behaviour to those calculated using the 660/910 nm sensor.
Figure 5.14 does however show much improved precision, taking into account that
the 740/880 nm sensor has a less sensitive calibration curve compared to that of the
660/910 nm sensor. R values calculated from the 740/880 nm sensor's PPG would
have had to be much more repeatable than R values from the 660/910 nm sensor's
PPG, as small changes in R would result in large SpgO2 changes. Improved low
saturation repeatability using the 740/880 nm sensor was veriﬁed by Mannheimer
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et al. (1997).
If the bias errors of the 740/880 nm sensor's low saturation data are consid-
ered, it seems that the empirical calibration curve is again more accurate than the
simulated calibration curve. The empirical and simulated bias and precision values
were -13.6±21.38% and -34.4±18.4%, respectively. Studies done by Zonios et al.
(2004) veriﬁed the empirical results by demonstrating that a traditional empirical
calibration curve also delivered low SpgO2 values when compared to the reference
ScgO2 values in the range of 20-60%.
5.3.4 Arterio-Venous Validation
The arterio-venous validation was done to determine the accuracy and validity of
the hypothesis that the overall absorption by two volumes of blood with diﬀering
oxygen saturations would be a linear combination of the individual saturation val-
ues. Validation was done by comparing the accuracy and repeatability of SpvO2
values calculated by means of empirical and simulated calibration curves, to ref-
erence ScvO2 values. Simulated arterio-venous calibration curves can be seen as
Figure 5.6. Only the 660/910 nm sensor was tested during this phase, due to time
constraints imposed by the testing procedure, as discussed in Section 4.6.2.
Arterio-venous validation, as explained in Section 4.6.2, was done by occluding
the blood supply to the subject's left hand after withdrawing a reference ScaO2
blood sample. Artiﬁcial PPG data induced by the APG on the subject's ﬁnger was
recorded and analyzed for SpvO2 using empirical and simulated calibration curves
that have been modiﬁed to take the reference ScaO2 values into account. ScvO2
values obtained from a venous blood sample was used as reference. Comparative
representations of ScvO2 and SpvO2 values measured for 12 subjects, is depicted in
Figures 5.16 and 5.17. All results presented are for an arterial-to-venous compliance
ratio of 1:1.
As can be seen from Figures 5.16 and 5.17, the calculated SpvO2 from both the
empirical and simulated calibration curves are not very accurate nor repeatable.
The empirical results do however show that for approximately 66% of the subjects,
SpvO2 values were within 10% of the reference.
Bias and precision values for the empirical and simulated calibration curves,
after the statistical outliers were removed, were 0.5±7.18% and -10.9±8.14%, re-
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Figure 5.16: Empirical In Vivo Arterio-Venous Results (In Vitro Curve)
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Figure 5.17: Empirical In Vivo Arterio-Venous Results (Simulated Curve)
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spectively. Qualitatively, this indicates that the empirical calibration curve is more
accurate than the simulated. As the arterio-venous calibration curves were directly
derived from the arterial calibration curves presented in Figures 5.2 and 5.7, bias er-
rors in these curves would also have propagated into the arterio-venous calibration
curves.
The precision issues can most likely be attributed to discrepancies in arterial-
to-venous ratios between diﬀerent subjects, as well as PPG variants as a result of
intrinsic APG behaviour which can be attributed to its design. These issues will
be discussed in more detail in Section 5.4.
5.4 Discussion
In pulse oximetry, the accuracy of any SpO2 measurement is dependent on the ac-
curacy of the pulse oximeter's calibration curve. This is the approach followed by
most pulse oximter manufacturers and the reason behind using an in vivo calibra-
tion procedure. In the scope of this study however, this approach was not possible,
with an in vitro approach being followed instead. This in vitro approach also has
its drawbacks however, with the mismatch of optical properties, as explained by
Mannheimer et al. (1997), being a major contributor. A photon diﬀusion simula-
tion was conducted to investigate the eﬀect that these property mismatches would
have on calibration curves. Calibration curves for the in vitro calibration and sim-
ulation of the 660/910 nm and 740/880 nm sensors are shown in Figures 5.18 and
5.19. Figure 5.18 also shows the simulated calibration curves for subjects 3 and 7
based on physiological parameters.
As can be seen from Figure 5.18, the in vitro calibration curve and the simulation
curve calculated by using the physiological properties of the in vitro calibration, are
remarkably similar. In adapting the simulation for a ﬁnger diameter of 10 mm, the
calculated curve did not deviate signiﬁcantly in the saturation range 80-100%. The
calibration curves presented by Schmitt (1991) also shows good correlation with
in vivo commercial calibration curves. It can thus be concluded that the in vitro
calibration curve is a relatively good substitute for an in vivo calibration curve in
the high saturation range, veriﬁed by the accuracy and repeatability of the SpaO2
results presented in Figure 5.10. It has to be noted however, that the bias in SpaO2
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Figure 5.18: 660/910 nm Empirical and Simulated Calibration Curve Comparison
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Figure 5.19: 740/880 nm Empirical and Simulated Calibration Curve Comparison
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using the in vitro calibration curve is -4.8%, which is more than the ±1-2% for
conventional in vivo curves. The errors in SpaO2 values presented in Figure 5.10
are most likely due to the use of a blood phantom to simulate optical transmission
through tisue.
The empirical and simulated calibration curves obtained for the 740/880 nm
sensor were not similar, as can be seen in Figure 5.19. The simulated calibration
curve was however similar to results presented by Mannheimer et al. (1997). The
constant DC oﬀset between the curves, was most likely caused by hardware related
issues such as the emitting intensity discrepancy between the selected 740 nm and
880 nm LEDs or LED emitting angle diﬀerences.
Figure 5.18 also displays the large deviations in calibration curves that vari-
ations in physiological parameters can cause at low saturations. The simulated
curves presented were calculated by using subject speciﬁc physiological parameters
measured during the in vivo validation phase. It was noted that these deviations
were only noticeable in the saturation range 0-80%. This indicated that the in
vitro calibration curves would not be accurate in the low saturation range, as the
physiological parameter changes between the in vitro calibration and in vivo val-
idation would have a pronounced eﬀect on the calibration curve. The inaccuracy
of the empirical and simulated calibration curves can be clearly seen in the results
presented in Figures 5.12 to 5.15. Accuracy seemed to be best when using the
empirical calibration curves for both the 660/910 nm and 740/880 nm sensors, in-
dicating that photon diﬀusion theory, or alternatively the optical constants used,
while being able to provide qualitative information on calibration curve behaviour,
is most likely not an accurate representation of light propagation through human
tissue in low saturation scenarios.
The accuracy and repeatability errors of the in vivo low saturation measure-
ments could also have been aﬀected by the operating principle of the pressure cuﬀ.
Even though the APG has been shown in Figure 5.9 to be eﬀective in generating
pulsatile blood behaviour in the ﬁnger, some design issues still exist. By ﬁxing the
cuﬀ diameter by means of Velcro strips, no repeatable and sustainable method was
available to ensure that each pneumatic pressure pulse would induce a repeatable
blood pulse. If, for instance, the pressure cuﬀ was ﬁxed to ﬁt more tightly around
subject 1's ﬁnger than subject 2's ﬁnger, the pressure exerted on subject 1's ﬁnger
would be greater than that exerted on subject 2's ﬁnger. Blood pulses in subject
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1's ﬁnger would thus have a greater amplitude than in subject 2's ﬁnger. This eﬀect
was also noticeable during individual PPG data acquisition periods as the Velcro
yielded under stress. It was thus not possible with the current design to ensure
that all artiﬁcial blood pulses had similar pulse volumes, a factor that has a major
eﬀect in low saturation scenarios where physiological parameter variations have a
major inﬂuence on sensor performance (Mannheimer et al., 1997). Variations in a
subject PPG and its eﬀect on R can be seen in Figure 5.20
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Figure 5.20: APG eﬀect on R
When comparing low saturation results for the 660/910 nm and 740/880 nm
sensors, it is evident that the 740/880 nm sensor has much improved repeatability
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over the 660/910 nm sensor. This can be noted from Figure 5.14 where, even though
the majority of the data points are lower than the reference, the data points are
spaced closer together than the data points in Figure 5.12. Additionally, the lower
sensitivity of the 740/880 nm sensor's calibration curve requires the R values to
be spaced closer together to achieve the same saturation repeatability than that
required for the 660/910 nm sensor.
The arterio-venous results, although not very repeatable, do seem to indicate
that the measurement of SpvO2 is possible, taking into account that an arterial-
to-venous compliance ratio of 1:1 was used as ﬁrst approximation throughout the
calculations.
Interestingly, it can be noted from Figure 5.16 that all ±1-2% calculations that
are outside the range ScvO2±10% are much lower than the reference. This may be
due to inaccurate calibration curves at the mid saturation range, inaccurate arterial-
to-venous ratios or pneumatic pressure discrepancies caused by the pressure cuﬀ
design, as described above.
To demonstrate the eﬀect of the arterial-to-venous compliance ratio, take the
SpvO2 values measured for subject 2 as an example. The ﬁrst SpvO2 value was
calculated at 51% with a reference ScvO2 of 82%. If the arterial-to-venous ratio is
changed from 1:1 to 1:5, the calculated SpvO2 value equals 70%. This is analogous
to the novel arterio-venous hypothesis stated as Equation 4.1. With SpvO2 con-
tributing to a larger extent to the SpmO2, the calculated SpvO2 is higher than with
the original arterial-to-venous compliance ratio of 1:1. Similar improvements can
be shown for all low SpvO2 values.
Pneumatic pressure discrepancies may also have a pronounced eﬀect on SpvO2
measurements. In the arterio-venous hypothesis, it is assumed that the pressure
exerted on the ﬁnger is higher than systolic pressure and that an artiﬁcial pulse
is thus induced in both the arterial and venous circulation. This assumption is
only valid if the pressure cuﬀ's diameter is suﬃciently small to ensure eﬃcient
pressure transmittance from the higher-than-systolic pneumatic pressure in the
cuﬀ to the ﬁnger. If the Velcro yields during data acquisition or the cuﬀ is too
loosely adjusted around the ﬁnger, the pressure transmitted to the ﬁnger may be
insuﬃcient to induce an artiﬁcial pulse in the arterial circulation. This would cause
the `combined arterial and venous R' to be representative of only venous pulsations.
If a SpaO2 is used in conjunction with this venous R, the calculated SpvO2 would
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be much lower than the reference ScvO2.
Chapter 6
Conclusion and Recommendations
6.1 Conclusion
The availability of continuous and non-invasive blood oxygen saturation informa-
tion will provide surgeons and medical practitioners with a valuable tool in mak-
ing intervention decisions regarding ischaemic tissue. In patients suﬀering from
meningococcemia, this decision is vital as the spread of ischaemic conditions in
peripheries is often rapid.
Pulse oximetry, the current benchmark for non-invasive measuring of SaO2,
has limited application in these ischaemic tissues, due to low SaO2 values and
low perfusion conditions. This study attempted to address these limitations by
developing an artiﬁcial pulse oximeter capable of accurately measuring both SaO2
and SvO2 in low saturation and perfusion scenarios.
A 660/910 nm LED pair and a 740/880 nm LED pair sensor were designed to
provide accuracy at both high and low saturations, respectively. The absence of an
AC component in the PPG was addressed by incorporating an APG into the design
to induce an artiﬁcial AC component. SaO2 and SvO2 were calculated according
to an arterio-venous hypothesis dependent on arterial-to-venous compliance. The
APO was calibrated for both high and low saturation ranges using an empirical in
vitro calibration approach. APO validation was done by means of in vivo studies.
A theoretical model, based on photon diﬀusion theory, was used to validate both
calibration and validation results.
It can be concluded from this study that the in vitro calibration technique
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followed is relatively accurate in high saturation scenarios, but that accuracy is
still inferior to an in vivo calibration approach. The theoretical model showed
close correlation with the 660/910 nm sensor's calibration curve at high saturation,
indicating that photon diﬀusion theory is an accurate representation of light propa-
gation in tissue at high saturation. Theoretical and empirical results did not agree
for the 740/880 nm sensor, which is most likely due to inaccurate optical constants.
Results obtained for both the 660/910 nm and the 740/880 nm sensors showed
bias and precision errors at low saturation. The 740/880 nm sensor did however
show superior precision when compared to the 660/910 nm sensor at low satura-
tion. It can thus be concluded that the 740/880 nm sensor is better suited for low
saturation scenarios.
The validation of the arterio-venous hypothesis showed bias and precision errors
for SvO2. When it is considered however, that these calculations were based upon
an initial approximation of arterial-to-venous compliance, the results indicate that
the APO is capable of measuring SvO2.
Although the results presented in this study are neither comprehensive nor
entirely conclusive, it is the opinion of the author that the accurate determination
of SaO2 and SvO2 with the APO would be possible with minor improvements to
ensure a more standardized measurement method.
6.2 Recommendations
The simulation, calibration and validation results, presented in Chapter 5, indi-
cate that accuracy and repeatability are problematic areas for the APO system,
especially in low saturation scenarios. It is however the opinion of the author
that certain improvements can be made to the hardware, the calibration and the
validation procedure to improve the overall APO performance.
6.2.1 Hardware Recommendations
In the design of the 740/880 nm sensor, the LEDs as speciﬁed in Appendix A, was
used. As can be seen from the datasheets in Appendix A, the ELS-740-994 LED
has a speciﬁed radiant power of 6,5 mW at a forward current of 50 mA, while the
ELS-880-894 LED has a speciﬁed radiant power of 12 mW at the same forward
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current. Radiant intensity is also speciﬁed for the ELS-880-894 LED, but not the
ELS-740-994 LED and is most likely not similar. These emittance discrepancies
between the LEDs were probably the cause for the large discrepancies between
the empirical and theoretical calibration curves presented in Figure 5.19. Even
though the eﬀects of diﬀerences in radiant power and intensity parameters would be
present and eliminated during the calibration phase, it still results in an inaccurate
theoretical explanation of curve behaviour and as such, only adds to calibration
curve uncertainty. It is thus recommended that alternative 740 nm and 880 nm
LEDs, with similar operating parameters, are used.
As explained in Section 5.4, the design of the pressure cuﬀ might have aﬀected
the accuracy and repeatability of the APO system. The main issue was the inability
to standardize the cuﬀ diameter before and during PPG data acquisition. This
resulted in diﬀering pneumatic pressures being exerted on subjects, even though
pneumatic pressure in the APG could be controlled. A complete redesign of the
pressure cuﬀ is recommended. An improved concept is shown in Figure 6.1.
Figure 6.1: Improved Pressure Cuﬀ Concept
In Figure 6.1, the pressure cuﬀ consists of a rigid ring, a pressure cuﬀ and high
and low pressure ports. The containing ring is suﬃciently large to accommodate
ﬁngers of varying diameters and serves to limit the outside diameter of the pressure
cuﬀ. The pressure cuﬀ is situated on the inside of the containing ring and is large
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enough to completely ﬁll the space on the inside of the containing ring if fully
inﬂated.
The deﬂated prototype is slid over the ﬁnger in the manner indicated in Fig-
ure 6.1. The pressure cuﬀ is inﬂated to an initial and controllable pressure. This
low starting pressure provides an accurate and repeatable starting condition. By
designing the pressure cuﬀ to be suﬃciently large to ﬁll the space on the inside
of the containing ring, the pressure cuﬀ will expand to adapt to the ﬁnger's di-
ameter and eﬃciently transfer pressure pulses to the ﬁnger. The containing ring
provides a rigid outside parameter to improve accuracy and repeatability during
APG operation.
The high and low pressure ports are included to provide a complete APO sys-
tem to measure SpaO2 and SpvO2 in normal perfusion and hypoperfusion scenarios.
Low pressure pneumatic pulses, but at higher pressure than the starting pressure,
are transmitted through the pressure cuﬀ to measure SpvO2 with the 740/880 nm
sensor. By ensuring that the pressure is lower than systolic blood pressure, the
blood pulses will only be induced in the venous circulation, causing R to be depen-
dent only on venous pulsations. SpvO2 can then be calculated by using a calibration
curve that is accurate at low or mid range saturations. Higher than systolic pres-
sure pulses are then transmitted through the pressure cuﬀ to measure SpaO2 using
the SpvO2 values calculated earlier, the arterio-venous hypothesis as stated in Sec-
tion 4.6 and accurate arterial-to-venous compliance ratios. The 660/910 nm sensor
will be used for this purpose. The combined arterial and venous R is analyzed for
SpaO2 using a 660/910 nm arterio-venous calibration curve. Low and high pres-
sure pulses are applied at frequencies that ensure minimal interference from normal
systolic pulses.
Compressed air will be stored in two separate pressure vessels to provide the low
and high pressure air. These pressure vessels will be large enough to ensure that
the high air demand will not result in pronounced pressure drops in the system,
while the compressor's air supply rate will be suﬃcient to meet the demand. The
starting, low and high pressure within the system will be continuously monitored
to ensure the correct operation of the system.
The modiﬁed system, as stated above, will only be suited for use on a digit. For
use on a limb or part of the trunk, the design would have to be modiﬁed to enable
eﬀective pressure transfer to the tissue.
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An alternative to the arterio-venous hypothesis presented in this study would
be the ﬁve wavelength system proposed by Aoyagi (2003). The system as proposed
by Aoyagi (2003) aims to eliminate or minimize the eﬀect of motion artifacts on
pulse oximeter performance. In doing so, the system possibly opens the way for
the determination of SpvO2 without the need for the arterio-venous hypothesis and
its accompanying compliance ratio uncertainties. As the ﬁve wavelength system
is dependent on arterial and venous pulsations, the system should still be used in
conjunction with the APG. The dual-wavelength sensor would then be replaced
with a ﬁve wavelength alternative.
6.2.2 Calibration Recommendations
The in vitro calibration curves presented in Figures 5.7 delivered high saturation
values that were relatively repeatable when compared to the reference, as shown
in Figure 5.10. Accuracy was, however, not good when compared to commercial
pulse oximeters that exhibit much lower errors (Zonios et al., 2004). Commercial
pulse oximeter calibration curves are obtained by utilizing an in vivo calibration
procedure. It is thus recommended that the 660/910 nm sensor is calibrated for
high saturation using an in vivo calibration approach.
For low saturation scenarios, the in vitro calibration setup discussed in Sec-
tion 4.5.2 can be modiﬁed to minimize the pronounced eﬀect that physiological
parameter variations have on curve behaviour at low saturations. The in vitro
setup can be modiﬁed so the experimental parameters closely resembles physio-
logical parameters. The cuvette depth could, for instance, be increased to 10 mm
to more accurately resemble actual physiological ﬁnger diameter data. Hematocrit
could also be closely controlled around the normal 45% value. Resident blood vol-
ume in the cuvette could be controlled by pressurizing the milk chamber. A higher
milk pressure will ensure a lower blood volume and vice versa. Milk pressure would
have to be closely monitored and controlled to deliver repeatable results. Addi-
tional procedures that reduce pressure and ﬂow velocity related artifacts could also
be included in the calibration setup (Edrich et al., 2000).
A factor that could also contribute to in vitro calibration curve inaccuracy, is
RBC haemolysis. It was noted that lactate levels in the blood used during the
calibration runs, rose to high levels at the completion of the runs. Increased lactate
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levels are a good indication of RBC haemolysis. Haemolysis would have the eﬀect
of altering the scattering coeﬃcient the blood, modifying the light propagation
properties of the blood. It is thus recommended that only whole blood that has
normal lactate levels is used during the calibration phase.
Alternatively, the occlusion studies done as part of the in vivo validation phase,
as explained in Section 4.6.2, can be used to obtain a low saturation in vivo cal-
ibration curve. A factor to watch out for would be the volume of the artiﬁcial
blood volume pulse. The APG generates a pulse in both the arterial and venous
circulations, approximately doubling the blood volume pulse. This could have a
major eﬀect on the calibration curve. Another issue could be discrepancies between
SaO2 and SvO2 after the occlusion period has passed. If SaO2 and SvO2 values are
not very similar when the PPG data is collected, the calibration curve will not be
accurate at low saturations due to the fact the both saturations have an eﬀect on
the calculated R.
6.2.3 Validation Recommendations
As noted in Section 6.2.2, diﬀerences in SaO2 and SvO2 values during the in vivo
low saturation validation phase could have a major eﬀect on R values. This eﬀect is
due the the fact that R is dependent on both SaO2 and SvO2. Alternative validation
studies, such as the in vivo studies done on sheep by Zonios et al. (2004), should
be considered.
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    EPIGAP Optoelektronik GmbH, D-12555 Berlin, Köpenicker Str. 325 b, Hs. 201, Tel.: +49-30-6576 2543, Fax.: +49-30-6576 2545
SMD LED ELS-740-994 
Radiation Type Technology Case
Infrared TOP LED AlGaAs/AlGaAs PLCC-2 
Description
High-power, high-speed, 
double heterostructure with removed substrate 
Applications
Optical communications, 
safety equipment, automation
2,2 ± 0,1
2,8 ± 0,2
Ø
 2
,4
 ±
 0
,2
3
,1
 ±
 0
,2
1,9 ± 0,2
3
,5
 ±
 0
,2
0
,8
0,15 0,5 ± 0,2
1
2
2
Cathode
Anode
Anode
ELC-67
Maximum Ratings 
Tamb = 25°C, unless otherwise specified 
Parameter Test conditions Symbol Value Unit
Forward current (DC)  IF 50 mA 
Peak forward current (tPd50 µs, tP /T = 1/2) IFM 100 mA 
Surge forward current (tPd10 Ps) IFSM  1000 mA 
Reverse voltage IR=100 µA VR 5 V 
Operating temperature range  Tamb -40...+85 °C 
Storage temperature range  Tstg -40…+90 °C 
Optical and Electrical Characteristics 
Tamb = 25°C, unless otherwise specified 
Parameter
Test
conditions
Symbol Min Typ Max Unit
Forward voltage IF = 50 mA VF  2.0 2.5 V 
Radiant power IF = 50 mA ĭe  6.5  mW 
Peak wavelength IF = 50 mA Op  740  nm 
Spectral bandwidth at 50% IF = 50 mA 'O0.5  30  nm 
Viewing angle IF = 50 mA 2M  120  deg. 
Switching time IF = 50 mA tr, tf  30  ns 
Figure A.1: ELS-740-994 Datasheet
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    EPIGAP Optoelektronik GmbH, D-12555 Berlin, Köpenicker Str. 325 b, Hs. 201, Tel.: +49-30-6576 2543, Fax.: +49-30-6576 2545
SMD LED ELS-880-894-3 
Radiation Type Technology Case
Infrared SMD AlGaAs/AlGaAs 0805 
Description
High-power, high-speed, 
double heterostructure with removed substrate 
Applications
Optical communications, 
safety equipment, automation
1,25
2
,0
1
,4
0,4
0,8
0
,4
Anode
Marking
Back side
1,2
1
,2
0,9
Recommended soldering
pattern
Unit: mm
Tolerance: 0,1mm
Maximum Ratings 
Tamb = 25°C, unless otherwise specified 
Parameter Test conditions Symbol Value Unit
Forward current (DC)  IF 50 mA 
Peak forward current (tP d 100 µs, tP /T = 1/10) IFM 100 mA 
Peak forward current (tP d 100 µs, tP /T = 1/100) IFM 500 mA 
Reverse voltage IR = 100 µA VR 5 V 
Power dissipation  PD 80 mW 
Operating temperature range  Tamb -40...+85 °C 
Storage temperature range  Tstg -55…+85 °C 
Optical and Electrical Characteristics 
Tamb = 25°C, unless otherwise specified 
Parameter
Test
conditions
Symbol Min Typ Max Unit
Forward voltage IF = 50 mA VF  1.4 1.9 V 
Radiant power IF = 20 mA ĭe  4.8  mW 
Radiant power IF = 50 mA ĭe  12  mW 
Radiant intensity IF = 20 mA Ie  1.2  mW/sr 
Radiant intensity IF = 50 mA Ie  4.0  mW/sr 
Peak wavelength IF = 50 mA Op 860 875 890 nm 
Viewing angle IF = 50 mA M  120  deg. 
Switching time IF = 100 mA tr, tf  25  ns 
Figure A.2: ELS-880-894-3 Datasheet
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Figure B.1: Photodiode Ampliﬁer (Orcad Capture)
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Figure C.1: Top Cuvette Component (AutoDesk Inventor 9)
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Figure C.2: Base Cuvette Component (AutoDesk Inventor 9)
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Figure C.3: Middle Cuvette Component (AutoDesk Inventor 9)
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Figure C.4: Cuvette Seal (AutoDesk Inventor 9)
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Figure C.5: Cuvette Assembly (AutoDesk Inventor 9)
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Table C.1: Part Catalogue Numberss
Part System Supplier Catalogue ID #
Compressor APG Mantech Elec. QJT-27QB 2
Non-return Valve APG Festo H-QS-6 2
T-Fitting APG Festo TJK-1/4 1
Push-in Fitting APG Festo QS-1/4-4 1
Push-in Fitting APG Festo QS-1/4-6 3
Push-in Fitting APG Festo QS-1/8-4 1
Push-in Fitting APG Festo QS-1/8-6 1
Push-in Fitting APG Festo QS-M5-6 3
Sleeve APG Festo QM-1/4-1/4 1
Accumulator APG Festo CRVZ5-0.4 1
Pressure Sensor APG Festo SDE1-D2-G2-WQ4-C-P2-M8 1
Pressure Lead APG Festo SIM-M8-4GD-2.5-PU 1
Valve Bank APG Festo BMFH-3-5-M5 1
Valve Solenoid APG Festo MSFG-24DC/42AC 3
Solenoid Lead APG Festo KMF-1-24DC-2.5-LED 3
Flow Regulator APG Festo GR-QS-6-LF 3
Relay APG Mantech Elec. FRS1-S 4
Sleeve Pressure Cuﬀ Festo QM-1/8-1/8 3
Push-in Fitting Pressure Cuﬀ Festo QS-1/8-6 3
Barbed Fitting Pressure Cuﬀ Festo CN-1/8-PK6 3
Push-in Fitting Cuvette Festo QSM-M3-4 2
Barbed Fitting Cuvette Festo CN-1/8-PK4 2
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Table D.1: In Vivo Validation Results for High SO2
Subject Trial Signal R SpaO2 Reference
# Qualitya Stabilitya Curve ∆ Simb ∆ ScaO2
1 1 + 0 96 0 95 -1 96
2 1 + 0 89 -7 87 -9 96
2 2 + + 90 -6 89 -7 96
2 3 0 + 92 -4 91 -5 96
3 1 - - - - - - 92
4 1 - - - - - - 95
5 1 0 0 91 -2 89 -4 93
5 2 + - 83 -10 80 -13 93
5 3 + 0 89 -4 87 -6 93
5 4 0 0 91 -2 90 -3 93
6 1 + + 96 -1 95 -2 97
6 2 + + 95 -2 95 -2 97
6 3 + + 95 -2 94 -3 97
7 1 + + 90 -5 89 -6 95
7 2 + + 89 -6 87 -8 95
7 3 + + 90 -5 88 -7 95
8 1 + + 91 -3 90 -4 94
8 2 + + 92 -2 91 -3 94
8 3 + 0 88 -6 86 -8 94
8 4 0 + 92 -2 91 -3 94
9 1 + + 93 -2 92 -3 95
9 2 + + 91 -4 90 -5 95
9 3 + + 88 -7 85 -10 95
10 1 + + 92 -2 91 -3 94
10 2 0 + 92 -2 91 -3 94
10 3 + 0 91 -3 90 -4 94
11 1 0 + 91 -3 90 -4 94
11 2 0 + 91 -3 89 -5 94
12 1 - - 85 -11 82 -14 96
12 2 + 0 82 -14 78 -18 96
12 3 0 - 83 -13 80 -16 96
a(+) Good; (0) Average; (-) Bad
bSimulation variable values dependent on subject
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Table D.2: In Vivo Validation Results for Low SO2 (660/910 nm)
Subject Trial Signal R SpgO2 Reference
# Qualitya Stabilitya Curve ∆ Simb ∆ ScgO2
1 1 - - 0 -32 0 -32 32
2 1 - - 10 -32 0 -42 42
3 1 0 - 66 +34 63 +31 32
4 1 0 - 37 -24 39 -22 61
4 2 + + 42 -19 43 -18 61
5 1 + 0 31 -20 14 -37 51
6 1 + 0 0 -30 0 -30 30
7 1 + - 27 0 9 -18 27
7 2 + + 40 +17 23 -4 27
8 1 - - 44 +25 26 +7 19
9 - - - - - - - -
10 1 0 - 19 -20 0 -39 39
11 1 + + 62 +9 50 -3 53
12 1 + + 65 +31 53 +19 34?
a(+) Good; (0) Average; (-) Bad
bSimulation variable values dependent on subject
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Table D.3: In Vivo Validation Results for Low SO2 (740/880 nm)
Subject Trial Signal R SpgO2 Reference
# Qualitya Stabilitya Curve ∆ Simb ∆ ScgO2
1 1 0 - 85 +53 50 -18 32
2 1 + + 26 -16 0 -42 42
3 1 - - 7 -25 0 -32 32
4 1 + + 29 -32 0 -61 61
4 2 + + 18 -43 0 -61 61
5 1 + + 21 -30 0 -51 51
6 1 + + 9 -21 0 -30 30
6 2 + + 11 -19 0 -30 30
7 1 + + 34 +7 2 -25 27
7 2 0 + 37 +10 5 -22 27
8 1 0 + 0 -19 0 -19 19
8 2 0 0 14 -5 0 -19 19
9 - - - - - - - -
10 1 0 + 19 -20 0 -39 39
10 2 + + 4 -35 0 -39 39
11 1 + + 35 -18 2 -51 53
11 2 + + 39 -14 5 -48 53
12 1 0 + 25 -9 0 -34 34?
12 2 + + 25 -9 0 -34 34?
a(+) Good; (0) Average; (-) Bad
bSimulation variable values dependent on subject
APPENDIX D. NUMERICAL IN VIVO VALIDATION RESULTS 133
Table D.4: In Vivo Arterio-Venous Validation Results
Subject Trial Signal R SpvO2 Reference
# Qualitya Stabilitya Curve ∆ Simb ∆ ScvO2
1 1 + + 83 +1 73 -9 82
2 1 0 - 51 -31 37 -45 82
2 2 0 + 72 -10 60 -22 82
3 1 0 0 72 +12 59 -1 60
4 1 0 0 78 +10 66 -2 68
5 1 + + 79 +2 67 -10 77
6 1 0 + 94 +6 89 +1 88
7 1 - - 87 -6 76 -17 93
8 1 0 0 78 -6 64 -20 84
9 1 + + 80 -3 67 -16 83
9 2 + + 55 -28 40 -43 83
10 1 - - 80 -1 68 -13 81
11 1 0 - 56 -36 40 -52 92
11 2 + - 0 -92 0 -92 92
12 1 0 - 42 -39 30 -51 81
12 2 0 - 44 -37 31 -50 81
a(+) Good; (0) Average; (-) Bad
bSimulation variable values dependent on subject
